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Danshen is the dried root of Salvia miltiorrhiza Bge, which has been widely used for 
the treatment of cardiovascular and cerebrovascular diseases. Exaggerated 
anticoagulant effects and bleeding complications have been observed in patients 
during concurrent use of danshen and warfarin. The present study investigated the 
possible underlying mechanism(s) of the interactions between danshen and warfarin. 
The effects of a danshen extract, aqueous and ethanolic extracts of danshen, 
tanshinone I，tanshinone IIA and cryptotanshinone on warfarin metabolism were 
investigated in vitro using rat liver microsomes, pooled human liver microsomes and 
human CYP2C9 isoform. In vivo pharmacokinetic studies in the rats were carried out 
to compare how danshen extract, when coadministered at different stages of warfarin 
treatment, may affect the metabolism of warfarin. 
In the rat liver microsomes study, the danshen extract, the ethanolic extract of 
danshen, tanshinone I, tanshinone IIA and cryptotanshinone decreased the formation 
of 4，-，6- and 7-hydroxywarfarin. This suggested that danshen extract and some of its 
lipid-soluble components affected the CYP-mediated warfarin metabolism by 
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inhibiting the activity of CYPlAl, CYP2C6 and CYP2C11 isoforms, which are 
mainly responsible for 4，-，6- and 7-hydroxylation of warfarin in the rat. The aqueous 
extract of danshen did not show inhibitory effect on the formation of warfarin 
metabolites. Cryptotanshinone was the most potent and showed a pure competitive 
inhibition. The inhibition of tanshinone I and tanshinone IIA seemed to involve more 
complicated inhibitory mechanisms. 
In studies using pooled human liver microsomes and human CYP2C9 isoform, the 
danshen extract, aqueous and ethanolic extracts of danshen, tanshinone I, tanshinone 
IIA and cryptotanshinone inhibited the formation of 7-hydroxywarfarin, which was a 
probe marker for assessing CYP2C9 activity. Nevertheless, the aqueous extract was 
found to reduce the formation of 7-hydroxywarfarin in human liver microsomes but 
not in rat liver microsomes. The ethanolic extract was more effective than the 
aqueous fraction to inhibit the warfarin metabolism. Tanshinone I was the most 
potent inhibitor in the studies. 
In the single dose metabolic study in vivo, both acute and subchronic danshen 
pretreatment significantly decreased Cmax and prolonged Tmax of warfarin in the rats. 
The alteration of Cmax and Tmax indicated that the danshen extract has affected the 
pharmacokinetics of warfarin. In addition, the formation of 4'- and 7-
hydroxywarfarin were decreased significantly after subchronic danshen pretreatment. 
In the steady state metabolic study in vivo, the plasma warfarin concentration 
increased significantly after danshen treatment by 23%. These suggest that danshen 
extract m a y inhibit the C Y P l A l , C Y P 2 C 6 and C Y P 2 C 1 1 mediated warfarin 
metabolism in vivo in the rats. 
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In conclusion, our studies showed that the danshen-warfarin interactions may have 
an underlying metabolic basis, that are relevant to the clinically important drug-
interactions in man. Obviously, some components of danshen inhibited warfarin 
metabolism in both pooled human liver microsomes and human CYP2C9 isoform. In 
addition, the rat studies showed good correlation with the human studies in vitro. 
However, the in vivo studies in the rats demonstrated the timing of danshen extract 
intake may have different effects on warfarin. Patients should advise their 
practitioners whether they have taken danshen or other T C M with their warfarin 
therapy and their prothrombin time and INR value should be measured regularly to 
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Traditional Chinese Medicine (TCM) has been developed in China for over 2,000 
years. T C M is a complex system of concepts and theories on the diagnosis and 
treatment of diseases, totally different western medicine. Actually, T C M is a broad 
subject that includes acupuncture, herbal medicine, massage and Qigong. Here, we 
define T C M as the Chinese herbal medicine, which is the most commonly used for 
treating disease and maintaining health。Most patients use the Chinese herbal 
medicine based on family tradition, professional recommendation or self-medication 
(Ergil et al, 2002). Although T C M has a very long history, there was little 
international support of its use until recently when more research work was carried 
out on T C M . More scientific data has proved that the effectiveness of T C M therapies 
and its value is recognized with T C M studies. The World Health Organization ( W H O ) 
has also acknowledged the value of T C M to facilitate the treatment of many diseases, 
either alone or as a supplement to western medicine. 
1.1.1 Origin, processing and delivery form of TCM 
T C M is widely used in the Chinese communities worldwide for treating diseases and 
maintaining health. Many commonly used herbs are derived from plants, minerals 
and animal products. As disease was thought to be caused by many factors, a 
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combination of several crude herbs is usually prescribed. These herbs possess 
different characteristics and active components, which can interact together and 
enhance the overall efficacy for curing disease. Besides, some herbs can reduce the 
toxicity of other herbs when used in combination. However, some herbs may reduce 
the efficacy and even induce the toxicity of other herbs. As an adverse herb-herb 
interaction is possible, practitioners should have knowledge on the nature of herbs 
and their effects before making any prescriptions. 
Most T C M are processed before use and the different ways by which they are 
processed can affect the efficacy of herbs. Firstly, natural herbs may contain toxic 
substances or impurities, which can induce toxicity or side effect. Some herbs cannot 
be stored for a long period of time as they deteriorate easily. Besides, some of them 
must be processed before meeting therapeutic requirements. There are two major 
types of processing, water processing and heat processing. The aims of water 
processing are to clean, soften and reduce toxic content of herbs. For heat processing, 
herbs are exposed directly or indirectly to fire. Heat can help to reduce the toxicity 
and extract the active ingredients of herb. In addition, some herbs can be processed 
with both water and heat, like steaming, boiling and scalding. 
Various delivery forms are available for T C M . For the same prescription, different 
delivery forms can exert different effects on the treatment. The water decoction is the 
most common delivery form because it can be absorbed easily. This is usually 
prepared by boiling herbs with water for several hours to extract the active 
ingredients. The liquid is collected and taken orally. Depending on the nature and 
properties of herbs, different preparation procedures for the same prescription may 
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be necessary. Pills and capsules are another common delivery form when the herbs 
are ground into powder and packed. Nowadays, herbal extract is also produced after 
herbs are boiled repeatedly and the solution obtained is concentrated to produce tonic 
or spray-dried concentrates. It is more convenient to take these forms than preparing 
a decoction and they are usually applied on treating chronic diseases, like liver and 
coronary diseases. 
1.1.2 Problems about the uses of TCM 
1,1,2A Quality control 
Quality control is one of the major concerns with the use of T C M because it is 
difficult to standardize the quality of natural herb or herbal formulation. The 
prescription of herbal medicine usually includes a mixture of herbs, with many 
different kinds of active ingredients. Different parts of plant, like root, stem and leave, 
may have different chemical compositions. Besides, the chemical composition of 
herb is influenced by several factors, such as climate, soil, growing condition, 
harvesting time, storage and processing method (Barnes, 2003). Therefore, batch-to-
batch and manufacturer-to-manufacture variations for the same herbal products do 
exist. It is complicated but important to monitor the quality of herbal prescription. 
A standardized quality control system for T C M will help its development and 
entrance to the international market. Chemical analysis methods like high pressure 
liquid chromatography (HPLC), gas chromatography (GC) and mass spectrometry 
(MS) can be applied to identify compounds and composition (Natile & Peter, 1998). 
Besides, D N A fingerprinting techniques can be used for the authentication of herbs 
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and identify the genetic make up of herb. This can improve its botanical identity and 
reliability. These techniques are also applicable on herbal pills or extracts, which are 
commonly used today but their botanical identity cannot be proved by traditional 
morphological inspection (Hon et al., 2003). Some manufacturers standardize the 
quality of products by monitoring the quantities of several active ingredients. 
1 丄2.2 Efficacy 
Efficacy is another important concern with the use of T C M . As previously mentioned, 
a herbal prescription usually consists of several herbs, containing many active 
ingredients (Phillipson, 1994). These active ingredients may interact with each other 
to provide the therapeutic effect. Therefore, it is difficult to assess its efficacy by 
western drug development standards, which only involve a single compound. To 
ensure the safe use of T C M , different experimental models should be set up to study 
the pharmacology and toxicology of T C M in a more systematic manner. Few clinical 
trials were done on T C M and the data only can be extrapolated to the preparation of 
herbs with similar profile of chemical constituents (Barnes, 2003). Besides, people 
usually prepare the herbal decoction themselves but they do not have a good 
understanding about the proper way of preparation and therefore it is difficult to have 
a standardized preparation process (Ho, 2001). Dosage is another problem that 
different proportions of herbs in the prescription can have great influence on its 
efficacy (Ho, 2001). 
1.1.2.3 Herb-drug interactions 
Chinese herbal medicine is usually self-administered or used as health supplement in 
Chinese communities. It is possible that herb-drug interactions may occur if a patient 
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consumes herbal medicine with other drugs. The result of such interactions can either 
increase or decrease the pharmacological or toxicological effects of drug, and may 
lead to treatment failure and adverse effects. A number of herb-drug interactions 
were observed in clinics, but there are lack of experimental data about the 
mechanism of the interaction. Most of interactions came from clinical case reports. 
To avoid any potential herb-drug interactions, clinicians should ask whether their 
patients consume herbal supplement and monitor their health condition regularly. 
L 1.2,4 A uthentication 
Some herbal products available may contain other pharmaceutical agents (Adams, 
2003). This is because pharmaceutical companies want to enhance the apparent 
effect of herbal products. However, this practice may confuse customers, affect the 
efficacy of original herbs and even cause adverse effects. It was reported that 30% of 
arthritis remedies and analgesics available in herbal stores in Taiwan contained drugs 
such as paracetamol, ibuprofen and phenylbutazone, which can cause side effects in 
patients (Dharmananda, 1994). Therefore, it is difficult to judge the effectiveness of 
T C M . As those drugs added are not labelled in the packing, the government should 
have a monitoring system on the quality of herbal products to ensure its safety. 
1.1.3 Commonly used Traditional Chinese Medicine 
Although there are still many unknowns about the use of T C M , many people still 
consume T C M for treating diseases and maintaining health, as they believe T C M has 
it own value and fewer side effects compared to the western medicine. Table 1.1 




































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































1.2 Interactions between TCM and warfarin 
Most of the evidence of TCM-drug interactions came from clinical cases. However, 
with the increasing use of T C M as complementary therapies, it is important to study 
the underlying mechanisms of such TCM-drug interactions. Warfarin is one of the 
most common anticoagulants used. Patients who are receiving warfarin therapy 
should be closely monitored on their International Normalized Ratio (INR) value and 
prothrombin time (PT) to ensure the effectiveness and safety of the treatment. As 
warfarin has a narrow therapeutic index, drug-drug interactions can easily occur and 
most of the adverse effects were caused by inhibition of its metabolism due to the 
perturbation of P450 enzymes (Williamson, 2003). In addition, there have been some 
clinical cases which involved the interactions between T C M and warfarin (Table 1.2). 
It is important to investigate the mechanism(s) of these TCM-warfarin interactions, 
in order to prevent any undesirable interaction effects during concurrently use of 

































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































1.21 Danshen-warfarin interactions 
Several cases of danshen-warfarin interactions were reported in the Prince of Wales 
Hospital in Hong Kong (Chan, 2001). A 66-year-old-man, who had taken warfarin 2-
2.5 mg/d for 14 months with INR about 2.0, was shown bleeding from the gastric 
carcinoma and his INR increased to 5.5 after admission (Tarn et al., 1995). He 
reported that he had consumed decoction of danshen and used medicated topical oil 
(methyl salicylate) for three and five days before admission. The INR of a 48-year-
old woman taking warfarin (4mg/d) increased to 5.6 after taking danshen and some 
other herbs every other day for one month (Yu et al., 1997). Danshen was believed to 
be the only agent that caused over-anticoagulation, which prolonged for at least 5 
days. A 62-year-old man, who had received chronic warfarin therapy (5mg/d) with 
stable INR at approximately 3.0, was admitted to hospital with pleural and 
pericardial effusion (Izzat et al., 1998). His INR was > 8.4 and he reported taking a 
decoction of danshen daily for two weeks before admission. 
Other animal studies also showed that danshen extract affected the pharmacokinetic 
and pharmcodynamic effects of warfarin enantiomers (Chan et al., 1995). In the 
study, it was found that the pharmacokinetics of R- and S-warfarin were significantly 
altered after danshen extract treatment. In a steady state study, the mean plasma 
concentrations of both R- and S- warfarin and the prothrombin time in the rats were 
significantly increased after the addition of danshen extract to the treatment schedule 




Danshen is the dry root and rhizome of Salvia miltiorrhiza Bge, family Labiatae. It is 
officially listed in the Chinese Pharmacopoeia and classified as a "Blood-
invigorating" herb which, in Traditional Chinese Medicine (TCM) concept, is non-
toxic and slightly cold in nature. Danshen is believed to have several functions. 
Firstly, it can promote blood circulation and remove stasis. It is widely used for 
treatment of coronary artery diseases, particularly angina pectoris and myocardial 
infraction (Tang, 1992; Wang, 1983). Besides, it has also been used in menstruation 
disorders, to relieve pain in acute arthritis and pathogen induced inflammation. It can 
also relieve restlessness and is used in the treatment of insomnia (Xu & Wang, 2002). 
1.3.1 Chemical constituents 
The active components of danshen can basically be divided into lipid-soluble and 
water-soluble fractions. The lipid-soluble fraction is rich in diterpene quinone 
pigments, with about 40 diterpene quinones having been isolated and identified 
(Zhou, 1993). The major chemical constituents in this fraction include tanshinone I, 
IIA and IIB，cryptotanshinone, 9-hydroxytanshinone II, isotanshinone I, IIA and IIB, 
isocryptotanshinone and methyl tanshinoate. Other minor chemical constituents were 
also isolated from danshen, including tanshindiol A, B and C, danshenxinkum A, B, 
C and D, miltionone I and II, miltirone and salviol. A series of water-soluble 
compounds were isolated from the aqueous extract of danshen, including 
protocatechualdehyde, danshensu, salvianolic acid A, B and C, lithospermic acid and 
rosmarinic acid (Zhou, 1993). 
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The major active components of danshen in commercially available crude danshen 
extract and danshen-containing preparations showed great variations, as indicated by 
the large standard deviations in their concentrations (Zhang et al., 2002), The 
variation may be a result of different growth conditions, such as soil, water, humidity 
and temperature, and growth stages when being harvested (Zhou et al., 1992). For 
other formulated oral preparations and injections of danshen, variation in the 
components of danshen and contents may be mainly due to different processing and 
extraction methods of danshen during production. The type of extraction method 
used has a significant effect on the extraction efficiency and thus the content of 
extract (Pan et al., 2002). The composition of major lipid-soluble and water-soluble 
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Tanshinone I Tanshinone IIA Tanshinone IIB 
mZ Me 丄 e Me 
Cryptotanshinone Isotanshinone I Dihydroisotanshinone I 
Figure 1.1 Chemical structures of some lipid-soluble compounds found in danshen 
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Danshensu Salvianolic acid A 
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。h 
OH 
Salvianolic acid B 
Figure 1.2 Chemical structures of some water-soluble compounds found in danshen 
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1.3.2 Pharmacological effects of danshen 
1,3,2,1 Anti-oxidant effects 
One of the major pharmacological effects of danshen is related to its anti-oxidant 
effect, which may be useful in the treatment of myocardial ischemic diseases where 
cellular damages were usually associated with the generation of reactive oxygen 
species (Marczin et al, 2003). Danshen scavenged oxygen free radicals generated 
from ischemia-reperflision in the myocardium, thus protecting the myocardial 
mitochondrial membranes from ischemia-reperflision injury and lipid peroxidation 
(Zhao et al., 1996). Danshen significantly reduced the area of cerebral infarct in 
ischemia-reperfusion injury in the rats through its free radical scavenging effect (Lo 
et al., 2003). It also reduced the myocardial infract size of acute myocardial 
infraction rats (Ji et al., 2003). Besides, danshen extract increased the anti-oxidant 
defense enzymes activities such as superoxide dismutase (SOD), catalase (CAT), 
glutatione perioxidase (GSH-Px) and glutathione S-transferase (GST), in the liver of 
rat with acute myocardial infarction (AMI), suggesting that the strong scavenging 
effect of danshen was due to increasing activities of various anti-oxidants enzyme 
systems (Ji et al,, 2003). 
For isolated danshen constituents, magnesium tanshinoate B (MTB) showed strong 
anti-oxidant effect by inhibiting the oxidative modification of low-density 
lipoproteins (LDL) and preventing the uptake of L D L by cultured macrophages 
(Lynn et al., 2001). Salvianolic acid A also inhibited the human L D L oxidation (Liu 
& Liu, 2002c). This is useful for protecting cells from lipid peroxidation in vascular 
disease. Salvianolic acid B showed protective effect against ischemia-reperfusion 
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induced rat brain injury by reducing lipid peroxides, scavenging free radicals and 
improving the energy metabolism (Chen et a/., 2000). Danshensu scavenged 
superoxide anion free radicals generated from xanthine and xanthine oxidase, while 
tanshinones scavenged lipid free radicals generated from lipid peroxidation (Zhao et 
al., 1996). All these scavenging effects protect the mitochondrial membrane from 
ischemia reperfusion injury. 
1.3,2.2 Effects on liver fibrosis 
Danshen has been used in the treatment of liver diseases such as chronic hepatitis 
and hepatic fibrosis. Several studies indicated that danshen and its isolated 
components are potential anti-fibrotic agents in experimental models. The water 
extract of danshen reduced hepatic fibrosis induced by carbon tetrachloride (CCI4) 
and bile duct ligation (Nan et al., 2001; Wasser et al” 1998). Tanshinone I induced 
apoptosis of rat hepatic stellate cell (HSC), which plays a central role in hepatic 
fibrosis, by activation of caspase through cytochrome C release and loss of 
mitochondrial membrane potential (Kim et al” 2003). Salvianolic acid A and B are 
the main effective anti-fibrotic constituents of danshen, which have strong 
antiperoxidative action. For salvianolic acid A, it had antiperoxidative effect on 
injured hepatocytes in liver injury and fibrosis induced by CCI4 (Liu et al., 2001). 
Besides, it inhibited cell proliferation and collagen production in cultured H S C (Liu 
et al., 2000). Salvianolic acid B inhibited the transforming growth factor-beta I, 
(TGF-beta I) signalling in H S C and this may be a significant anti-fibrotic mechanism 
(Liu et al., 2002a). 
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1.3.2.3 Effects on tumours 
Tanshinones are mainly responsible for the anti-tumour activity of danshen and their 
effects have been studied for many years. They showed significant cytotoxicity 
against many types of human carcinoma cell line, for examples, A549 (non-small 
cell lung), SK-OV-3 (ovary), SK-MEL-2 (melanoma), XF498 (central nerve system) 
and HCT-15 (colon) (Ryu et al., 1997). Different isolated tanshinones showed 
different degrees of cytotoxicity. Tanshinone I and IIA exhibited stronger 
cytotoxicity against P388 lymphocytic leukemia cells than dihydrotanshinone I and 
cryptotanshinone (Mosaddik, 2003). Tanshinone IIA showed cytotoxic activity 
against many kinds of human carcinoma cell line. It induced differentiation, 
apoptosis, inhibited invasion and metastasis of cancer cells (Yuan et al., 2003). 
Salvinal isolated from danshen, showed inhibitory activity against tumour cell 
growth and induced apoptosis in various human cancer cells, through inhibition of 
tub 1 in polymerization (Chang et al., 2004). 
1.3.2.4 Effects on cardiovascular system 
The cardiovascular effects of danshen had been studied extensively. Danshen 
induced a dose-related hypotension without changing the heart rate in the rats, an 
effect which was antagonized by atropine, propranolol, chlorpheniramine and 
cimetidine (Lei & Chiou, 1986a). Both danshen extract and isolated tanshinones 
showed similar effect on rat and rabbit blood vessels in vitro, causing vasodilation of 
the coronary arteries, renal mesenteric and femoral arteries with different extents 
(Lei & Chiou, 1986b). Danshensu dilated the isolated swine coronary artery and 
antagonized the constricting response elicited by morphine and propranolol (Dong & 
Jiang, 1982). Sodium tanshinone IIA sulfonate, a water soluble derivate of 
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tanshinone IIA, attenuated hypertrophy by suppressing angiotensin induced 
enlargement of cultured rat myocytes (Takahashi et al., 2002). 
1.3.2.5 Effect on platelet aggregation 
The crude extract of danshen was found to inhibit the platelet aggregation in the 
rabbits (Liu et al” 2002b). Salvianolic acid A inhibited the collagen-induced platelet 
aggregation in the rats. Besides, it also inhibited the platelet aggregation in vitro, 
induced by collagen, A D P and A A (Tang et al., 2002). Tanshinone IIA sodium 
sulfonate inhibited ADP-induced platelet aggregation of the blood in patients (Wang, 
1983). 
1.4 Warfarin 
Warfarin is one of the most widely used oral anticoagulants for the prevention and 
treatment of thromboembolic disorders (Hirsh, 1991). It is highly effective in 
preventing recurrent diseases such as venous thrombosis and pulmonary embolism 
(Hyers et al,, 2001). Besides, warfarin is superior to aspirin in preventing stroke in 
patients with atrial fibrillation (Connoly et aL, 1991). It is important to manage the 
warfarin dose in order to provide the beneficial anticoagulation without increasing 
the risk of haemorrhage. As warfarin has a narrow therapeutic index and its 
involvement in drug-drug interactions is common, international normalized ratio 
(INR) of patients should be monitored frequently to ensure the safety and 




Warfarin is one of the 4-hydroxycoumarin derivatives and is an antagonist of vitamin 
K. The anticoagulant effect of warfarin is mediated by interfering with the cyclic 
interconversion of vitamin K and vitamin K (epoxide) in the clotting factor synthesis 
(Fig 1.3) .Vitamin K is a cofactor for the post-translation y-carboxylation of glutamic 
acid residues to y-carboxyglutamic acid residues in the vitamin K-dependent clotting 
factors II, VII, IX and X (Fasco et al., 1982; Whitlon et al., 1978). Without the 
carboxylation of glutamine acid resides on these factors, these factors are biological 
inactive. In the vitamin cycle, the reduced form of vitamin K (hydroquinone) is 
oxidized to vitamin K (epoxide) during carboxylation of clotting factor. Afterwards, 
vitamin K (epoxide) is reduced back to vitamin K (hydroquinone) by two reductase 
steps. Warfarin is structural similar to vitamin K and thus it is a competitive inhibitor 
for vitamin K epoxide reductase. The first reductase step is more sensitive to vitamin 
K antagonist compared to the second reductase step (Choonara et al., 1998). By the 
inhibition of this enzyme, less vitamin K (hydroquinone) is available for the clotting 
synthesis and thus provides the anticoagulant effect. However, it should take at least 
1 week for the normal clotting factor to clear and reach the equilibrium level before 
providing a stable anticoagulant effect on patients (O'Reilly & Aggeler, 1968). The 
warfarin dose also should be adjusted very carefully because its dose-response 
relationship varies between patients, that is affected by genetic and environmental 
factors, for examples, mutation of gene coding in C Y P P450, dietary change and 
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Warfarin is administered clinically as a racemic mixture that contains both R- and S-
enantiomers. It has high oral availability of >95% that the peak absorption occurs at 
around 90 minutes (Hirsh at al., 2001). Warfarin is highly bound to plasma proteins, 
mainly albumin, with values ranging from 97 to 99.5% and thus has a small 
distribution volume (0’ Reilly, 1973). Any drug that displaces warfarin from the 
protein-binding site can increase the free plasma concentration of warfarin and lead 
to bleeding complication (Hirsh, 2001). Enantiomers of warfarin are metabolized 
mainly by hepatic mixed function oxidase cytochrome P450 (CYP) system in 
different pathways and their metabolites are eliminated in the bile and urine. S-
wafarin is five times more potent than R-warfarin in its anticoagulant action in man. 
However, S-warfarin is cleared more rapidly, with its half-life between 18-35 hours 
while the half-life of R-warfarin is 20-60 hours (Hignite et al., 1980). The mean 
plasma half-life is approximately 40 hours. Therefore, the effect of a single dose 
warfarin lasts for two to five days, with maximum effect starts 48 hours after 
administration (Hignite et al., 1980). 
1.4.3 Metabolism 
C Y P is a major enzyme system for the metabolism of warfarin (Kaminsky et al., 
1984). It is also an important phase I drug-metabolizing enzyme system that has 
different specific isoforms for the metabolism of xenobiotics and endogenous 
substances. The in vitro metabolism of warfarin has been extensively studied by 
using purified P450, liver microsomal preparation and cDNA-expressed recombinant 
human P450 (Kaminsky & Zhang, 1997). It was found that enantiomers of warfarin 
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are metabolized into monohydroxylated metabolites stereoslectively and 
regioselectively by different C Y P isoforms (Kaminsky, 1989; Trager, 1989). 
Three C Y P isoforms (CYP1A2, CYP2C9 and CYP3A4) are predominantly 
responsible for Phase I metabolism of warfarin. CYP1A2 catalyzes R-warfarin to 
produce 6- and 8-hydroxywarfarin. CYP1A2 is highly regioselective on 6-
hydroxlation of R-warfarin, 6-hydroxywarfarin is the major metabolite produced in 
cDNA-expressed human CYP1A2 (ratio of 6-OH to 8-OH is 5) (Zhang et al., 1995). 
Other important C Y P isoforms, like 2C9, 2D6, 2E1 and 3A4 did not yield either 6-
or 8-hydroxywarfarin from R-warfarin metabolism. This makes the formation rate of 
6-hydroxywarfarin a good marker for measuring human hepatic CYP1A2 activity 
(Zhang et al., 1995). CYP3A4, which is the most abundant C Y P isoform (30%) in 
human liver, is another important C Y P for R-warfarin metabolism that catalyzes R-
warfarin to yield 10-hydroxywarfarin (Kaminsky & Zhang, 1997). For S-warfarin, it 
is mainly metabolized by CYP2C9 to yield 6- and 7-hydroxywarfarin. Besides, it 
was found that only CYP2C9 of 11 human P450 expressed HepG2 cells exhibited 
strong stereoselectivity and regioselectivity for S-warfarin 7-hydroxylation (Rettie et 
al,, 1992). Therefore, S-warfarin is usually used as a probe substrate for assessing the 
CYP2C9 activity. 
Apart from the P450 catalyzed reactions, reduction of the ketone side chain of 
warfarin is another Phase I metabolism of warfarin. About 15 to 20% of warfarin is 
reduced to disastereoisomeric alcohol by carbonyl reductase and excreted in the urine 
(Hermans & Thijssen, 1992). 
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There is little information about the conjugation of warfarin metabolites in phase II 
metabolism. In rat hepatocyte model, it was found that 4‘-hydroxywarfarin is 
converted to glucuronide conjugate, whereas 6-hydroxywarfarin occurred mainly as 
sulphate conjugate. In contrast, 7- and 8- hydroxywarfarin are converted to sulphate 
and glucuronide conjugates (Jansing et al, 1992). In human, 10-hydroxywarfarin is 
conjugated fully with glucuronide and sulphate, while 6- and 8- hydroxywarfarin are 
conjugated by 66% and 66 to 100% respectively in different patients (Kaminsky & 
Zhang, 1997). 
1.4.4 Warfarin-drug interactions 
As warfarin is a drug with a narrow therapeutic window, it interacts with many drugs 
and results in loss of anticoagulant control (Harder & Thurmann，1996). Drug 
interactions can be either pharmacokinetic or pharmacodynamic in nature. For 
pharmacokinetic interactions, coadministration of drugs can alter the absorption, 
distribution, protein binding and metabolism of warfarin. By applying appropriate in 
vivo or in vitro models, pharmacokinetic interactions can be studied. However, 
pharamcodynamic interactions are more complicated as it may involve specific 
receptor sites or the physiological processes at molecular level. 
1,4.4.1 Pharmacokinetic Interactions 
Many drugs may reduce the absorption of warfarin from the gastrointestinal tract by 
raising gastric pH, altering gastrointestinal motility and interfering with mucosal 
function. However, only cholestyramine was reported to reduce the absorption of 
warfarin significantly up to 30% (Serlin & Breckenridge, 1983). 
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Drugs can displace warfarin from albumin binding site and increase the free warfarin 
concentration in plasma. Phenylbutazone increases the plasma warfarin concentration 
significantly by displacing warfarin from binding site and inhibiting the metabolism 
of S-warfarin stereoselectively (Banfield et al., 1983; Koch-Weser & Sellers, 1976). 
Clofibrate displaces warfarin from protein binding sites, with an 13% increase in the 
free drug fraction in plasma (Bjomsson et al., 1979). 
The major cause of pharmacokinetic interactions for warfarin is the inhibition or 
induction of P450 C Y P isoforms. The stereoselective inhibition of metabolism of S-
warfarin is more significant than R-warfarin because S-warfarin is 5 times more 
potent than R-warfarin as vitamin K antagonist (Breckenridge et al., 1974). 
Phenylbutazone, sufinpyrazone, metronidazole, trimethoprim-sulfamethoxazole 
inhibited S-warfarin metabolism and increased the prothrombin time (0’ Reilly, 
1980a; 0' Reilly, 1976; Toon et al,, 1986). Cimetidine and omeprazole decreased the 
clearance of R-warfarin but only had a moderate potentiating effect on the 
prothrombin time (Niopas et al., 1999; Sutfin et al., 1989). Amiodarone inhibited 
both S- and R-warfarin metabolism and potentiated the anticoagulant effect of 
warfarin (Heimark et al., 1992). 
The induction of C Y P isoforms activity increased the clearance, decreased the 
plasma half-life and steady state concentration of warfarin, and thus reducing its 
anticoagulant effect. Barbiturate, carbamazepine and rifampin are CYP3A4 inducers 
that inhibit the anticoagulant effect of warfarin significantly (Niemi et al., 2003; 
Spina et al., 1996). 
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L4.4,2 Pharmacodynamic interactions 
The pharmacodynamic interactions of warfarin are related to different mechanisms. 
Firstly, increased vitamin K intake by consuming green vegetable or vitamin K 
containing supplements is sufficient to reduce the anticoagulant effect of warfarin (0' 
Reilly & Rytand, 1980b). On the other hand, decreased vitamin K intake can 
potentiate the anticoagulant effect in patients. Sulfonamides and antibiotics 
suppressed the production of vitamin K by gut bacteria and aggravate vitamin K 
deficiency (Magid, 1962). 
•estrogens increased the synthesis of clotting factors and thus reduce the effect of 
anticoagulant (Schrogie et al., 1975). However, anabolic steroids have shown 
opposite effect but the detailed mechanisms are unknown. Diuretics reduced the 
anticoagulant effect of warfarin by increasing the concentration of clotting factors 
(O'Reilly, 1980). Furthermore, clofibrate potentiated the action of warfarin by 
altering receptor sensitivity (〇’ Reilly et al., 1972). 
Drugs may affect the pharmacodynamics of warfarin by interfering haemostasis 
processes. Aspirin binds irreversibly to the active site of cyclooxygenase and inhibits 
platelet thromboxane A 2 biosynthesis. The impaired platelet function can prolong the 
bleeding time and potentiate the action of warfarin (Dale et al., 1980). Non-steroidal 
anti-inflammatory drugs such as phenylbutazone and indomethacin, inhibited the 
biosynthesis of prostaglandins that alter the normal haemostasis pathways (Schulman 
& Henriksson, 1989). 
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1.5 Aim of study 
Taken together the clinical reports and previous findings in animal studies, danshen 
has great potential to cause pharmacokinetic and pharmacodynamic interactions with 
warfarin. Patients are advised to avoid the use of danshen when receiving warfarin 
therapy. However, the mechanism(s) of the danshen-warfarin interactions remain 
unknown. The aim of the present study is to investigate the underlying mechanism(s) 
of the danshen-warfarin interactions by studying the effect of danshen extract, and 
some of its active components, on warfarin metabolism in vitro. Firstly, rat liver 
microsomes (Chapter 2) and human liver microsomes (Chapter 3) were used as in 
vitro models to investigate the effect of danshen extract and its components on 
warfarin metabolism by measuring the concentrations of warfarin metabolites and 
warfarin in the metabolic systems. Secondly, rats were used as in vivo model to study 
the effect of danshen extract on the pharmacokinetic of warfarin (Chapter 4). This 
will enable us to determine how the in vitro data may be extrapolate in vivo. This part 
of the study also investigated if the timing of the danshen-warfarin interactions m y 
be affected by steady state or non-steady state warfarin. Finally, a preliminary study 
on the effect of danshen extract on the absorption of warfarin by using Caco-2 cells 
absorption model (Chapter 5). This will provide an evidence on whether danshen 




Effects of danshen extract and some of its active ingredients 
on warfarin metabolism in rat liver microsomes 
2.1 Introduction 
As described in Chapter 1, danshen extract has been shown to interact with warfarin, 
in both pharmacokinetic and pharmacodynamic studies in the rats. Danshen extract 
increased the bioavailability of warfarin and decreased its elimination, suggesting 
that danshen extract can exaggerate the pharmacological effect of warfarin and cause 
significant clinical interactions (Chan et al., 1995). From the viewpoint of the 
underlying mechanism of the pharmacokinetic interaction, danshen extract may have 
affected absorption, distribution, metabolism and excretion of warfarin. In the 
present study, the metabolic interaction of danshen extract and some of its 
components with warfarin will be investigated in vitro by using metabolism models. 
In addition, their effects on the activity of cytochrome P450 (CYP) can also be 
understood. 
Cytorchrome P450 enzymes (CYP) are heme-containing proteins in the endoplasmic 
reticulum and mitochondria, mainly responsible for catalysing the phase I 
metabolism of endogenous substrates and xenobiotics (Nelson et al., 1996). C Y P 
usually catalyzes the reaction of a substrate, using atmospheric oxygen, in the 
presence of reduced cofactor (C0H2), such as N A D P H + H+. Finally, the substrate 
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has been converted into hydroxylated metabolites, which can be more easily 
conjugated for phase 2 reaction or excreted from the body. The C Y P catalyzed 
reaction can be expressed as: 
C0H2 + O2 +R-H — • Co + R - O H +H2O 
C Y P plays an important role in drug biotransformation with over 95% of drugs used 
clinically being metabolized by human CYPs 1A2, 2C9, 2D6, 2E1 and 3A4. Thus, 
drug-drug interactions may occur during coadministration of drugs, if one of the 
drugs affect the activity of the C Y P isoforms. In the case of enzyme inhibition, this 
may lead to accumulation of a drug, resulting in toxicity or exaggeration of the 
pharmacological actions. Treatment failure can result from enzyme induction in 
which drugs accelerate the enzyme synthesis, increasing the rate of metabolism and 
clearance of the drug. Inhibition of C Y P is recognized by U.S. Food and Drug 
Administration (FDA) and other agencies as an important cause of drug interaction. 
It was because C Y P plays a major role in the phase I metabolism, the rate 
determining step for drug metabolism. Besides, C Y P has broad and overlapping 
specificity that a particular C Y P can metabolize many different drugs. Therefore, 
inhibition of the activity of C Y P has a large tendency to interfere with the 
metabolism and thus clearance of co-administered drugs. 
Many in vitro systems have been used to study the inhibition on C Y P enzymes, such 
as liver microsomes, C Y P enzymes, hepatocytes and liver slices, with varying 
degrees of advantages and limitations. Rat liver micrsomes has been used as to 
predict the drug interaction potential of drugs before the relative high-cost of human 
liver samples was available. As species difference in C Y P system exists in the 
response of the drug metabolism between experimental rat model and man, it is 
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important to know the similarities and differences of their C Y P activities towards 
oxidation reactions (Shimada et ciL, 1997). Rat model was selected as a good 
metabolism model for studying CYP1A2 and CYP2E1 activities. However, it should 
be noted that the major C Y P forms in man, which are CYP3A4 and CYP2D1, are 
absent in the rats (Nedelcheva & Gut, 1994). 
Danshen extract was found to affect the pharmacokinetics of warfarin in the rats 
(Chan et al., 1995). The mechanism(s) of the interactions still remain to be 
established. In rat, R-warfarin is metabolized by CYPlAl to 6- and 8-
hydroxywarfarin, by CYP2B1 to 4'-hydroxywarfarin, by CYP2C6 to 7-
hydroxywarfarin, by CYP2C11 to 4，- and 6-hydroxywarfarin, and by CYP3A2 to 10-
hydroxywarfarin. S-warfarin is metabolized by CYPlAl to 6-hydroxywarfarin, by 
CYP2C6 to 7-hydroxywarfarin and by CYP2C11 to 4，- and 6-hydroxywarfarin. The 
major warfarin metabolites produced is 4,-, 6-, and 7- hydroxy warfarin. 
In this study, the potential of danshen extract and some of its active ingredients in 
affecting the in vitro metabolism of warfarin was investigated. Quantitation of the 
metabolites of warfarin (4'-, 6-, 7-, 8- and 10-hydroxywarfarin) will provide 
information on how danshen would affect the activities of different C Y P isoforms. 
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2.2 Materials and methods 
2.2.1 Chemicals and reagents 
Danshen extract was characterized and kindly donated by Winsor Health Products 
Limited (Hong Kong). Danshen root was purchased and authenticated from a local 
Traditional Chinese Medicine Store, Eu Yu Sang (Hong Kong). Tanshinone I, 
tanshinone IIA, cryptotanshinone were purchased from Chengdu Congon Bio-tech 
Co., Ltd (China). Warfarin, 4'-, 6-, 7-, 8-, 10-hydroxywarfarin, 7-ethoxycoumarin, p-
nicotinamide adenine dinucleotide phosphate (NADP), D-glucose 6-phosphate (G6P), 
glucose 6-phosphate dehydrogenase, cimetidine, sodium potassium tartrate, Folin 
and Ciocalteau's phenol reagent and bovine serum albumin (BSA) were obtained 
from Sigma Chemical Co. (St. Louis, M O , USA). Ammonia, magnesium chloride, 
sodium dihydrogenphosphate monohydrate, potassium chloride and potassium 
hydroxide were supplied by Merck (Darmstadt, FRG). Acetic acid was obtained from 
Schartau Chemie (USA). Sodium hydroxide was purchased from B D H Laboratory 
Supplies (Poole, England). Phenobarbitone sodium B.P. was obtained from Universal 
Pharmaceutical Lab., Limited (Hong Kong). Acetronitrile and methanol (both H P L C 
grade) were supplied by Mallinckrodt Baker Inc. (Paris, Kentucky, USA). Ethyl 
acetate was purchased from Fluka Chemicals (Buchs, Switzerland) 
2.2.2 Animals 
Male Sprague Dawley rats (250-280 g) were supplied by the Laboratory Animal 
Service Centre, The Chinese University of Hong Kong. Animals were housed with 
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alternating 12-hours light-dark cycles, with free access to standard laboratory food 
and tap water. 
2.2.3 Preparation of rat hepatic microsomes 
Rat liver microsomes were prepared using the method of Guengerich (Guengerich et 
al., 1982). All the procedures were carried on ice (0 to 4 °C). The rat was killed by 
cervical dislocation and the liver was removed and washed in ice-cold saline (0.9% 
NaCl w/v). The liver was then homogenized in ice-cold Tris/KCl buffer (2 ml per g 
of liver) (0.05M, p H 7.4) using a Polytron (Kinematica) PTlO-35 homogenizer. The 
tissue homogenate was centrifuged at 10,000 xg for 25 min by Beckman Avanti J-
251 centrifuge (rotar JA 25.5). The supernatant was collected and centrifuged at 
100,000 xg for 1 hour by Beckman L7-65 ultracentrifuge (rotor 45Ti). The 
supernatant was then discarded. The pellet was resuspended in Tris/KCl buffer (2 ml 
per g of liver) (0.05M, p H 7.4) and centrifuged at 100,000 xg for 1 hour. The liver 
microsomes pellet was resuspended in 5 ml of Tris/KCl buffer (0.05M, pH 7.4). The 
supernatant was collected and stored immediately in liquid nitrogen prior to use. 
Protein assay was carried out to determine the concentration of microsomal protein. 
About 20% liver-weight microsomes was obtained. 
2.2.4 Protein assay 
Protein concentrations of the liver microsomes were measured by the method of 
Lowry (Lowry et al., 1951). A standard curve for B S A in sodium hydroxide (0.5M) 
were prepared as standards, at 0, 25, 50, 100，150 and 200 |ig/ml. Sample (10 jal) was 
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diluted to 1: 100 by sodium hydroxide (990 jal, 0.5M). 5ml copper reagent, which 
contains copper (II) sulfate (0.063M), sodium potassium tartrate (0.07IM) and 
sodium carbonate in O.IM sodium hydroxide (0.189M), was added to 1 ml of B S A 
standard or sample. The mixture was incubated for 10 minutes at room temperature 
and then 0.5 ml Folin and Ciocalteau's phenol reagent (IN) were added. The mixture 
was mixed immediately and incubated for 30 minutes at room temperature. The 
absorbance of each standard was determined at 750 n m using the Pharmacia LKB-
Biochrom 4060 spectrophotometer and was plotted against the protein concentration. 
The absorbance of sample was recorded from the spectrophotometer and its protein 
concentration was read from the standard curve. 
2.2.5 Preparation of aqueous fraction and ethanolic fractions of danshen from 
danshen roots 
2,2.5.1 Aqueous extract of danshen 
Danshen was purchased and authenticated at a local T C M store (Eu Yu Sang). It was 
cut into small pieces before use. About 200g of danshen root was weighed and boiled 
with 250 ml water under reflux condition. After 1 hour, the mixture was filtered and 
the filtrate was collected. Another 250 ml of water was added to the danshen residue 
and boiled again for one more hour. Afterwards, all filtrate was collected and 
combined, and allowed to cool at room temperature. Powder form of the aqueous 
extract was obtained after freeze-drying of the filtrate under vacuum condition. 
About 35 g danshen aqueous extract was obtained with a yield of 17.5%. 
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2,2,5.2 Ethanolic extract of danshen 
The procedures for preparation ethanolic extract were similar to the preparation of 
water-soluble fraction. However, danshen root was boiled with 250 ml of 95% 
ethanol, instead of water, for two times under reflux. The filtrate collected was dried 
by a rotatory evaporator below 50 A brown red residue was obtained and re-
dissolved in ethyl acetate. The ethyl acetate layer was then pipetted out and collected 
for rotatory evaporation. About 2 g of brown red crystal was obtained and the 
percentage of yield was 1%. 
2.2.6 Incubation condition for warfarin metabolism 
The incubation mixture consisted warfarin (10.8 \Jil of 500 |Lxg/ml, 35 |aM), G6P (38 
)al of 100 mg/ml, 25 m M ) , N A D P (38 |al of 100 mg/ml, 10 m M ) , magnesium 
chloride (51 |il of 10 mg/ml, 5 m M ) and rat liver microsomes (3 mg/ml). The total 
volume was 500 made up by Tris/KCl buffer (0.05 M at pH 7.4). The mixture 
was pre-warmed at 37 °C for 5 minutes and then the reaction was started by adding 
glucose 6-phosphate dehydrogenase (5.4 \il of 200 units/ml, 1.08 units). The whole 
mixture was incubated at 37。C for 1 hour. To stop the reaction, 0.5 ml of ice-cold 
acetronitrile was added. The mixture was centrifuged at 13,000 rpm for 10 minutes to 
precipitate the microsomal protein. Afterwards, the supernatant was collected and 7-
ethoxycoumarin (10 ^ il of 50 |Lig/ml, 2.63 pmoles) was added as an internal standard. 
0.5 ml ethyl acetate was added for extraction of warfarin and warfarin metabolites. 
The whole mixture was shaken at 1,400 rpm for 30 minutes in a rotary apparatus and 
subsequently centrifuged at 13,000rpm for 10 minutes. The upper ethyl acetate layer 
was evaporated to dryness under a gentle stream of nitrogen at 40 Finally, the 
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residue was dissolved in 120 ^ il methanol and 50 was injected to the H P L C system 
for analysis. 
In preliminary experiments, it was found that the formation of warfarin metabolites 
were linear up to 8 mg/ml microsomes added over the 1 hour incubation time. 
Control experiments were set up in the absence of any one of the following 
substances in the incubation mixture, warfarin, G6P, G6P dehydrogenase, N A D P and 
liver microsomes. N o warfarin metabolites peak was detected for all control 
experiments. 
2.2.7 Effects of danshen extract and some of its active ingredients on warfarin 
metabolism in vitro 
Six danshen constituents were used in this in vitro experiment to study their effect on 
warfarin metabolism. These were danshen extract, aqueous and ethanolic extract of 
danshen and these isolated compounds, including tanshinone I, IIA and 
cryptotanshinone. 
Stock solutions of danshen constituents were prepared. Danshen extract and its 
aqueous extract were dissolved in the water as stock solution (2 mg/ml). While the 
ethanolic extract and the isolated danshen compounds such as tanshinone I, 
tanshinone IIA and cryptotanshinone were dissolved in dimethyl sulfoxide (DMSO) 
(20 mg/ml). For each sample, 2 |Ltl of components dissolved in D M S O was added and 
the final concentration of D M S O in the incubation mixture was 0.4 % . Besides, 2 iil 
of D M S O was added in the control. 
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The effect of danshen extract and aqueous extract on warfarin metabolism were 
studied at 0.5, 1.0, 1.5 and 2 mg/ml. For ethanolic extract, tanshinone I，tanshinone 
IIA and cryptotanshinone, their concentration effects were studied at 5, 10, 20，30, 40 
and 80 )ag/ml (corresponding molar concentration was shown in the Table 2.1). 
These compounds were added in the mixture with warfarin substrate (35 )aM) and 
other cofactors for incubation. Control was set up for comparison. In addition, the 
peak height ratio for warfarin and all warfarin metabolites were measured by H P L C 
and analyzed. 
^ L i g / m l 5 1 0 W ^ ~ ~ ~ 8 0 ^ 
m m — 
Tanshinone I ( M W 276.3) 36.19 72.38 144.77 289.54 579.08 
Tanshinone IIA ( M W 294.3) 33.98 67.96 135.92 271.83 543.66 
Cryptotanshinone ( M W 296.4) 33.74 67.48 134.95 269.91 539.81 
Table 2.1 Conversion of concentration units ()ag/ml to juM) for danshen isolated 
constituents. M W stands for molecular weight. 
2.2.8 Effects of danshen extract and some of its active ingredients on enzyme 
kinetics of wrfarin metabolism in vitro 
To study the mode of inhibition of danshen extract and its components on warfarin 
metabolism, warfarin (8 to 100 jLiM) was incubated with rat liver microsomes, in the 
presence of danshen inhibitors for obtaining enzyme kinetics data. Two different 
concentrations of danshen inhibitor were incubated for each set of experiments 
(danshen extract: 1 and 1.5 mg/ml, tanshinone I: 289.54 and 579.08 \iM, tanshinone 
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IIA: 271.83 and 543.66 |aM, cryptotanshinone: 16.87 and 33.74 The 
experimental procedures were carried out as described in section 2.2.7. The velocity 
of formation of metabolites was plotted against the substrate concentration. Apparent 
dissociation constant (Km) and maximal velocity (Vmax) were calculated by 
Michaelis-Menten equation, at different inhibitor concentrations. The Lineweaver-
Burk plot was used to find out the type of inhibition, if any, to calculate the Kj when 
appropriate. 
2.2.9 High Pressure Liquid Chromatography (HPLC) analysis 
The H P L C system for anaylsis of warfarin and warfarin metabolites was a 
modification method from Fasco (Fasco et al., 1977). The H P L C system consisted of 
a Hewlett Packard (HP) 1050 series pumping system, a multiple wavelength detector 
(UV detection at 313nm) and a Hamilton 802RN syringe loading sample injector 
with 50 \jil loop. The eluate was analyzed by passing though a guard column 
(Supelco PelliguardTM LC-18) and a reversed-phase C-8 column (Agilent Zorbax 
Eclipse XDB-C8, 150 m m x 4.6 mm). The mobile phase for the H P L C system was a 
mixture of 1.5% (v/v) acetic acid (pH 4.72, adjusted by concentrated ammonia) and 
acetronitrile. These solutions were filtered (Nylon 66 membranes 0.2 jum x 47 m m , 
Supelco Inc.) using a Buchner funnel under vacuum and then degassed for 5 minutes. 
The mobile phase was eluted by gradient mode with the flow rate at Iml/min and its 
proportion of 1.5% acetic acid and acetronitrile at various time intervals was shown 
in the Table 2.2. All experiments were performed at ambient temperature. 
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Time intervals (min) 0 1 3 5 6 9 U 
Percentage of acetic acid 80 80 70 70 ^ ^ 4 0 
Percentage of acetronitrile 20 20 30 ^ 45 ^ ^ 
Table 2.2 Composition of mobile phase in H P L C system after injection of sample 
Warfarin and its metabolites were well separated under this H P L C condition, as 
shown in Fig 2.2. The retention times for warfarin metabolites were about 8 to 9 




































































































































































































































































































































































2.2.10 Calibration curves and validation of the HPLC systems 
Calibration curves were constructed by spiking known amounts of standards into 
Tris/KCl buffer, together with 7-ethoxycoumarin as internal standard. The mixture 
was then treated as the entire sample preparation procedures. The standard 
concentration of warfarin ranged from 1 to 40 \xg/ml For other warfarin metabolites, 
the concentration ranged from 0.05 to 1.5 |Lig/ml. Eight unique concentrations were 
used to construct the calibration curve. After the H P L C analysis, the peak height 
ratio (peak height of analyte / peak height of internal standard) was calculated. This 
peak height ratio was plotted against concentration. The linearity of the standard 
curve was tested by liner regression analysis. The R-squared values for all analytes 
were greater than 0.98. 
The intra-day, inter-day precision and accuracy were carried out for warfarin and its 
metabolites (Table 2.3). The precision was calculated as the relative standard 
deviation. The accuracy was expressed as the percentage difference of the 
determined value from the nominal value. The recovery for all warfarin and its 
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Fig 2.4 Standard curve for 7-hydroxywarfarin 
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Fig 2.5 Standard curve for warfarin 
51 
Chapter 2 
2.2.11 Data analysis 
The significant difference between control and treated groups was analyzed by 
Student's t-test in the Statview version 9.0 (Abacus Concepts, USA). There was 
statistical significant difference if P<0.05. 
IC20, which was the concentration of drug required to produce 20% inhibition of the 
C Y P catalytic activities, was determined for each isolated danshen components by 
visual analysis on the plot of percentage of the formation control against inhibitor 
concentrations. 
The formation velocity (V) that was expressed as pmoles per minute per m g protein 
was plotted again the substrate concentration (S). It was fitted by non-linear 
regression analysis according to the Michaelis-Menten equation in GraphPad Prism 4 
(GraphPad Software, Inc. San Diego, C A , USA). 
Michaelis-Menten equation: V = Vmax [S] / ([S]+Km) 
Vmax and Km were the apparent maximal velocity and the apparent dissociation 
constant. Lineweaver-Burk plot was plotted (1/V against 1/S) to characterize the type 
of inhibition. Ki was calculated by the linear regression on the secondary plot, which 
was the plot of Km / Vmax against inhibitor concentration 




The accuracy, inter- and intra- precision were found to be less than 10% at 4 to 10 
l^g/ml for warfarin and 0.4 and 1.0 [xg/ml warfarin metabolites, indicating that the 
developed H P L C system was reliable to carry out quantitation analysis. Effects of six 
different danshen components on warfarin metabolism were investigated and 
compared. 4，-, 6- and 7-hydroxywarfarin were the major metabolites produced in the 
experiment and their concentrations were measured by H P L C for quantitative 
analysis. 8- and 10-hydroxywarfarin were below the detection limit (5 ng/ml) in our 
H P L C system. 
2.3.1 Effects of danshen extract on warfarin metabolism 
Danshen extract did not inhibit the formation of 4，-, 6- and 7-hydroxywarfarin at 0.5 
mg/ml. At 2 mg/ml, it reduced the formation of 4,- and 6-hydroxywarfarin 
significantly by 50%. Besides, it showed the greatest inhibition, which was 80%, on 
the formation of 7-hydroxywarfarin. (Fig 2.6) 
Formation rates of 4，-, 6- and 7-hydroxywarfarin in function of warfarin substrate 
concentrations were shown, with the corresponding Lineweaver-Burk Plots (Fig 2.7 
to 2.12). Km (dissociation constant) and Vmax (maximal velocity) values were 
calculated and shown in Table 2.4. From the secondary plot of KmA^max against 
inhibitor concentrations, danshen extract did not show pure competitive inhibition on 
the formation of 4'- and 6-hydroxywarfarin, as indicated by small R-square values 
after the linear regression on the data points. For the formation of 7-hydroxywarfarin, 
it seemed to be an uncompetitive inhibition that the slopes and intercepts of lines 
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increased as inhibitor concentrations. In addition, they intersected on the below the 
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Fig 2.6 Effects of danshen extract on the formation of warfarin metabolites by using 
rat liver microsomes, Values are mean 士 S E M of six rats, *p<0.05, **p<0.01 and 
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Warfarin concentration (|aM) 
Fig 2.7 Effects of danshen extract on the formation of 4‘-hydroxywarfarin at 
different warfarin substrate concentrations (n = 4) 
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Fig 2.8 The Lineweaver-Burk plot of the effects of danshen extract on the formation 
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Fig 2.9 Effects of danshen extract on the formation of 6-hydroxywarfarin at different 
warfarin substrate concentrations (n = 4) 
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Fig 2.10 The Lineweaver-Burk plot of the effects of danshen extract on the 
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Fig 2.11 Effects of danshen extract on the formation of 7-hydroxywarfarin at 
different warfarin substrate concentrations (n = 4) 
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Fig 2.12 The Lineweaver-Burk plot of the effects of danshen extract on the formation 




Control 1.5 mg/ml 2 mg/ml 
parameters 
• • '• • ••‘ ‘ ‘ I . I 丨丄丨丨 I • . . . . . L - , - ^ — ^ . ― —, •,„• — 丨，_•-•_. 1 , • ,,, . 
4,-hydroxywarfarin 
Km (luM) 184.70 ± 64.80 138.10 ±70.45 153.20 ±83.87 
Vmax (pmol/mg protein/min)44.66 ± 11.21 41.66 士 13.96 4L66± 13.56 
K m / Vmax ^ 
6-hydroxywarfarin 
K m ( ^ M ) 96.04 ± 55.51 85.56 ±39.81 99.07 ±48.01 
Vmax (pmol/mg protein/min) 35.06 土 11.80 29.00 ± 7.53 25.69 ±7.33 
Km / Vmax 2 ^ 6 ^ 
— . • • • I — — • ———— “ -- • ‘ ———— ‘ -
7-hydroxywarfarin 
Km(iaM) 77.84 ±22,72 62.68 ± 26.25 68.75 ±27.29 
Vmax (pmol/mg protein/min) 6 2 . 5 2 ± 9 . 8 3 4 3 . 9 4 ± 9 . 0 9 3 2 . 9 9 ± 6 . 7 2 
Km / Vmax L33 L M ^ 
Table 2.4 Enzyme kinetic parameters of the effects of danshen extract on the 
formation of 4，-, 6- and 7-hydroxywarfarin (n=4) 
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2.3.2 Effects of aqueous extract of danshen on warfarin metabolism 
Aqueous extract of danshen had no significant effect on the formation of 4，-, 6- and 
7-hydroxywarfarin at doses 0.5, 1, 1.5 and 2 mg/ml (Fig 2.13)，suggesting that the 






• mm 6-hydroxywarfarin 
^ M 7-hydroxywarfarin 
_ 
0.0 0.5 1.0 1.5 2.0 
Aqueous extract of danshen (mg/ml) 
Fig 2.13 Effects of aqueous extract of danshen on the formation of warfarin 
metabolites by using rat liver microsomes, Values are mean 士 S E M of six rats, 
*p<0.05, **p<0.01 and ***p<0.001 compared to control 
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2.3.3 Effects of ethanolic extract of danshen on warfarin metabolism 
At 5 and 10 |ig/ml of ethanolic fraction of danshen, no inhibition was found on the 
formation of 4'- 6- and 7-hydroxywarfarin. However, the formation of these 
metabolites was reduced in a dose-dependent manner from 20 to 80 [xg/m\ (Fig 2.14). 
Ethanolic extract of danshen (40 to 80 |ag/ml) reduced the concentration of 4'-
hydroxywarfarin reduced significantly by 35% to 58%. At the concentration range 
tested (20 to 80 ^ g/ml), the amount of 6-hydroxywarfarin also decreased from 17 % 
to 50%, while the amount of 7-hydroxywarfarin decreased more significantly from 
23 % and 77 % . The greatest degree of inhibition on the formation of 7-
hydroxywarfarin indicated that the ethanolic extract may inhibit the rat CYP2C6 
more than other C Y P isoforms. 
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0.7"! I I 4'-hydroxywarfarin 
T m i 6-hydroxywarfarin 
rj M m 7-hydroxywarfarin 
I i i i 
3 0.5- • • • * 
^m ^m 
芝 H 圓 圓 
• _ ^ ^ ^ ^ ^ ^ 
I。.4_ J I I � , 
丨 l i i k 
0 5 10 20 40 80 
Ethanolic extract of danshen (|ig/ml) 
Fig 2.14 Effects of ethanolic extract of danshen on the formation of warfarin 
metabolites by using rat liver microsomes, Values are mean 士 S E M of six rats, 
*p<0.05, **p<0.01 and ***p<0.001 compared to control 
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2.3.4 Effects of tanshinone I on warfarin metabolism 
Tanshinone I was found to have different inhibitory effects on the formation of 4’-， 
6- and 7-hydroxywarfarin. At 289.54 to 577.08 jiM, tanshinone I inhibited the 
formation of 4‘-hydroxywarfarin from 22 to 27%, while the formation of 6-
hydroxywarfarin from 17 to 27%, respectively. There was no significant difference 
in the formation of 7-hydroxywarfarin in this study (Fig 2.15). The results may 
indicate that tanshinone I may not inhibit CYP2C6 which mainly catalyzes warfarin 
to form 7-hydroxywarfarin. 
From the Lineweaver-Burk plot, tanshinone I seemed to be a mixed competitive 
inhibitor for the formation of 4,-, 6- and 7-hydroxywarfarin (Fig 2.16 to 2.21) (Table 
2.5). It was because poor linearity was obtained from those secondary plots (Km/Vmax 
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11116-hydroxywarfarin 
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Fig 2.15 Effects of tanshinone I on the formation of warfarin metabolites by using rat 
liver microsomes, Values are mean 士 S E M of six rats，*p<0.05, **p<0.01 and 
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Fig 2.16 Effects of tanshinone I on the formation of 4‘-hydroxywarfarin at different 
warfarin substrate concentrations (n 4) 
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1/[warfarin concentration, |iM] Fig 2.17 The Lineweave -Burk plot of he effects of tanshinone I on the formation of 
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Fig 2.18 Effects of tanshinone I on the formation of 6-hydroxywarfarin at different 
warfarin substrate concentrations (n = 4) 
0.8n 
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室 0.4- J / ！::/ 
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Fig 2.19 The Lineweaver-Burk plot of the effects of tanshinone I on the formation of 
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Warfarin concentration (jiM) 
Fig 2.20 Effects of tanshinone I on the formation of 7-hydroxywarfarin at different 
warfarin substrate concentration (n = 4) 
1.4-1 
• Control 
1.2- • / • 289.54 ^ M 
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I。.8- / 
i。.6- / 
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1 / [ w a r f a r i n c o n c e n t r a t i o n , | a M ] 
Fig 2.21 The Lineweaver-Burk plot of the effects of tanshinone I on the formation of 
7-hydroxywarfarin (n 二 4) 
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Enzyme kinetic parameters Control 289.54 _ 579.08 _ 
4'-hydroxy warfarin 
Km(iaM) 97.40 ±34.66 74.22 ±27.11 74.22 ± 22.94 
Vmax (pmol/mg protein/min) 2 0 . 1 2 ± 4 . 2 1 6 1 5 . 2 9 ± 2 . 9 8 1 2 . 9 3 土 2 . 4 5 ^ 
Km / Vmax ^ 
• 一 • _ _ _ " _ - • •• •• — s ^ a ^ a a •- - _ -••-•• •_• ••_-••••_ 丨-‘ -- __ „_ • ‘ , • • . •丨 •• = = = • • - •——-f-J-^-- , • — — — — — I - T T — T — T 
6-hydroxywarfarin 
Km(|uM) 90.46 ±20.25 76.38 ±24.50 66.32 ± 24.25 
Vmax (pmol/mg protein/min) 17.95 ±2.3 14.34 ±2.48 14.95 土 2.80 
Kn, / Vmax ^ 430 
7-hydroxywarfarin 
Km(iLiM) 110.8 ±62.20 116.2 士 71.26 84.53 ±53.82 
Vmax (pmol/mg protein/min)47.21 ± 16.29 41.32 ± 15.83 33.89 ± 12.08 
Km / Vmax ^ 
Table 2.5 Enzyme kinetic parameters of the effects of tanshinone I on the formation 
of 4，-, 6- and 7-hydroxywarfarin (n=4) 
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2.3.5 Effects of tanshinone IIA on warfarin metabolism 
Tanshinone IIA did not show any inhibitory effect on the formation of 4'-
hydroxywarfarin, indicating that it may not have affected the rat CYP2B1 and 
CYP2C11. However, at 135.92 and 543.66 juM tanshinone IIA, the formation of 6-
hydroxywarfarin decreased significantly by 20 and 21%, respectively. The greatest 
inhibitory effect was observed in the formation of 7-hydroxywarfarin that its 
concentration decreased from 33% to 40%, with tanshinone IIA (135.92 to 543.66 
I^M), suggesting that tanshinone IIA may affect the particular rat CYP2C6 pathway. 
Mixed competitive inhibition was suggested from the formation of 4，-, 6- and 7-
hydroxywarfarin from the visual observation on the Lineweaver-Burk plot (Fig 2.23 
to 2.28) (Table 2.6). 
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0 33.98 67.96 135.92 271.83 543.66 
Tanshinone IIA(jiM) 
Fig 2.22 Effects of tanshinone IIA on the formation of warfarin metabolites by using 
rat liver microsomes, Values are mean 土 S E M of six rats, *p<0.05, **p<0.01 and 
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Fig 2.23 Effects of tanshinone IIA on the formation of 4‘-hydroxywarfarin at 
different warfarin substrate concentrations (n = 4) 
1-0- • Control 
0.9- / • 271.83 _ 
I 0 8- • • 543.66 ^ M 
I 0:7- / / 
1/ 
-0.05 0.00 0.05 0.10 0.15 
l/[warfarin concentration, [iM] 
Fig 2.24 The Lineweaver-Burk plot of the effects of tanshinone IIA on the formation 
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I 6- ^^^^：：；：：^^^"^^^ • 543.66 jiM 
I： 
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0 10 20 30 40 50 60 70 80 90 100 
Warfarin concentration (|iM) 
Fig 2.25 Effects of tanshinone IIA on the formation of 6-hydroxywarfarin at 
different warfarin substrate concentrations (n 二 4) 
10- • Control 
0.9- • 271.83 |LIM 
I 0.8- • 543.66 ^ iM 
J 乙 
-0.05 0.00 0.05 0.10 0.15 
1/[warfarin concentration, | iM� 
Fig 2.26 The Lineweaver-Burk plot of the effects of tanshinone IIA on the formation 
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Warfarin concentration (|iM) 
Fig 2.27 Effects of tanshinone IIA on the formation of 7-hydroxywarfarin at 
different warfarin substrate concentrations (n — 4) 
• Control 
0.5-
• 271.83 \iM 
百 • 543.66 laM 
I 0.4- y 
^ , , , 
-0.05 0.00 0.05 0.10 0.15 
1/[warfarin concentration, |iM] 
Fig 2.28 The Lineweaver-Burk plot of the effects of tanshinone IIA on the formation 
of 7-hydroxywarfarin (n = 4) 
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Enzyme kinetic parameters Control 271.83 _ 543.66 i^M 
4'-hydroxywarfarin 
Km ( _ 44.64 ± 11.47 76.65 土 18.30 76.21 ±25.69 
Vmax (pmol/mgproteinymin) 10.58+1.12 14± 1.81 12.39 ±2.25 
Km / Vmax 4 ^ 9 ^ ^ 
6-hydroxywarfarm 
Km(|iM) 49.09 ± 15.77 52.32 ± 12.48 32.21 ± 13.85 
Vmax (pmol/mg protein/min) 1 0 . 0 8 ± 1 . 4 7 1 9 . 8 5 ± 1 . 1 0 7 . 3 5 ± 1 .21 
Km / Vn,ax ^ ^ 一 
7-hydroxywarfarin 
Kn,()iM) 18.15 ± 6.80 36.01 ± 14.40 32.22 ±17.19 
Vmax (pmol/mg protein/min) 17.23 ± 1.984 17.62 ±2.83 14.32 ±2.93 
Km / Vn,ax 0 9 ^ 
Table 2.5 Enzyme kinetic parameters of the effects of tanshinone IIA on the 
formation of 4,-, 6- and 7-hydroxywarfarin (n=4) 
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2.3.6 Effects of cryptotanshinone on warfarin metabolism 
Cryptotanshinone was found to have a greater inhibitory effect on warfarin 
metabolism, compared to other danshen extracts or components tested. At 33.74 to 
539.81 |j.M cryptotanshinone, the concentration of 4‘-hydroxywarfarin reduced 
significantly from 80 to 30%, while the concentration of 6-hydroxywarfarin reduced 
from 67 to 24%. Cryptotanshinone showed greatest inhibition on the formation of 7-
hydroxywarfarin that its concentration reduced from 73 to 14% (Fig 2.29). From the 
result, cryptotanshinone may have potent effect on several C Y P isoforms, like 
CYPlAl, CYP2B1, CYP2C6, CYP2C11, which are involved in the major formation 
of 4，-，6- and 7-hydroxywarfarin in the rats. 
From the Lineweaver-Burk plots, competitive inhibition was suggested for the 
cryptotanshinone on the formation for 4，-, 6- and 7-hydroxywarfarin as the slope of 
lines increased as inhibitor concentration and the lines intersected at the same point 
(Fig 2.30 to 2.35)(Table 2.7). This was confirmed again by the secondary plots that 
the line showed a very good linearity (R〉0.94). Kj was calculated based on the 
secondary plots that its value for 4’-, 6- and 7-hydroxywarfarin was 163.80, 58.68 
and 29.31 ]iM, respectively. The result indicated that cryptotanshinone is a strong 
competitive inhibitor for CYP2C6 for the formation of 7-hydroxywarfarin, while a 
relative weak competitive inhibitor for CYPlAl, CYP2B1 and CYP2C11 for the 
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Cryptotanshinone (|iM) 
Fig 2.29 Effects of cryptotanshinone on the formation of warfarin metabolites by 
using rat liver microsomes, Values are mean 士 S E M of six rats, *p<0.05, **p<0.01 
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Fig 2.30 Effects of cryptotanshinone on the formation of 4‘-hydroxywarfarin at 
different warfarin substrate concentrations (n = 4) 
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1/[warfarin concentration, }iM] Fig 2.31 The Lineweaver-Burk plot of the effects of cryptotanshinone on the 
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Fig 2.32 Effects of cryptotanshinone on the formation of 6-hydroxywarfarin at 
different warfarin substrate concentration (n — 4) 
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Fig 2.31 The Lineweaver-Burk plot of the effects of cryptotanshinone on the 
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Fig 2.34 Effects of cryptotanshinone on the formation of 7-hydroxywarfarin at 
different warfarin substrate concentrations (n = 4) 
1 • Control 
* • 16.87 ^ M 
1.2- / • 33.74 ^ M 
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Fig 2.31 The Lineweaver-Burk plot of the effects of cryptotanshinone on the 
formation of 4‘-hydroxywarfarin (n = 4) 
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Enzyme kinetic parameters Control 16.87 |iM 33.74 jiM 
4'-hydroxywarfarin 
Km(j^M) 52.84 ± 16.75 40.69 ± 13.24 37.99 ±11.77 
Vmax (pmol/mg protein/min) 1 1 . 8 4 士 1 . 7 6 9 . 8 4 ± 1 . 3 5 9 . 7 8 士 1 . 2 4 
Km / Vmax ^ ^ TM 
6-hydroxywarfarin 
K m O ^ M ) 5 9 . 5 7 ± 1 3 . 4 0 8 5 . 9 2 ± 2 2 . 2 3 5 6 . 1 4 士 1 3 . 6 8 
Vmax (pmol/mg protein/min) 1 3 . 3 3 ± 1 . 47 1 5 . 5 8 ± 2 . 2 7 1 1 . 7 1 士 1 . 3 7 ^ 
Km / Vmax ^ ‘ 
7-hydroxywarfarin 
K m ( ^ M ) 35.70 ±21.60 33.76 ±26.66 29.24 ±26.66 
Vmax (pmol/mg protein/min) 1 8 . 7 4 ± 4 . 5 3 1 6 . 0 3 ± 4 . 9 5 1 2 . 7 2 ± 3 . 0 3 
km / vmax 7^43 1 0 ^ 
Table 2.7 Enzyme kinetic parameters of the effects of cryptotanshinone on the 
formation of 4’-, 6- and 7-hydroxywarfarin (n=4) 
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2.3.7 IC20 of danshen extract and its components on warfarin metabolism 
IC20 was calculated instead the commonly used IC50 because some danshen 
components were not potent enough to achieve 50% inhibition on the formation of 
metabolites in our studied concentration. Therefore, IC20 was selected and used to 
compare the degree of inhibition (Table 2.8). 
Ethanolic extract was more potent than danshen extract which had IC20 value in jug 
level rather than m g level. For isolated components, tanshinone I was the least potent 
inhibitor that the IC20 values for the 4’-, 6- and 7-hydroxywarfarin were 225, 450 
and 500 ^ M , respectively. Tanshinone IIA inhibited the formation of 7-
hydroxywarfarin more than 4，- and 6-hydroxywarfarin that their IC20 values were 62, 
135 and 136 |nM, respectively. For cryptotanshinone, it appeared to be the most 
potent inhibitor among tanshinone I and IIA. The IC20 for cryptotanshinone on the 
formation of 4’-, 6- and 7-hydroxywarfarin were 34, 22 and 28 |iM, respectively. 
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IC20 4 '-hy droxywarfarin 6-hydroxywarfarin 7-hydroxywarfarin 
Danshen extract 
1.3 1.3 0.92 
(mg/ml) 




20 25 15 
Og/ml) 
Tanshinone I (^iM) 450 500 “ 
Tanshinone IIA 
135 136 62 
Cryptotanshinone 
34 22 28 
( _ 




Cytochrome P450 (CYP) comprises a superfamily of haemproteins that plays an 
important role in catalyzing the oxidation of many endogenous and exogenous 
substances, for examples, steroids, prostaglandins, drugs, carcinogens and 
environmental pollutants (Anzenbacher & Anzenbacherova, 2001). They are mainly 
involved in the Phase I biotransformation that oxidizes a compound to a more polar 
metabolite before eliminating from the body. A drug-drug interaction usually occurs 
as C Y P has broad substrate specificity and overlapping substrate selectivity. In 
addition, the activity of C Y P can be altered by either by induction or inhibition, 
affecting the normal metabolism and pharmacological action of coadminstered drugs 
(Guengerich, 1997). As there is increasing use of T C M in combination of western 
drugs in the community, it is necessary to study TCM-drug interactions at metabolic 
basics. In vitro and in vivo studies have been indicated that active ingredients in 
herbs or T C M interact with various C Y P isoforms extensively by acting as C Y P 
substrate, inducer or inhibitor (Zhou et al., 2003). 
Previous studies from Chan indicated that danshen extract increased the 
bioavailability but decreased the clearance of warfarin in the rat (Chan et al., 1995). 
This pharmacokinetic interaction suggests that danshen extract may alter the 
pharmacokinetics of warfarin by affecting the absorption, distribution, metabolism or 
excretion of warfarin. In the present study, the effect of danshen extract and its 
components on the metabolism of warfarin was studied by using rat liver 




In this study, the danshen extract showed significant inhibitory effect on the 
formation of 4，-, 6- and 7-hydroxywarfarin at mg/ml level. Since these warfarin 
metabolites are formed via CYP-mediated metabolism mainly by CYPlAl, CYP2B1, 
C Y P 2 C 6 and CYP2C11 isoforms in the rats, this suggests that high dose of danshen 
may inhibit these rat C Y P isoforms. The aqueous extract of danshen had no effect on 
the formation of hydroxywarfarin metabolites, indicating that the water-soluble 
active ingredients of danshen such as salvianolic acid A, B and danshensu may not 
inhibit the activity of C Y P enzymes. 
Ethanolic extract of danshen contains mainly tanshinones, which are responsible for 
the diverse pharmacological effects of danshen. It was much potent than the danshen 
extract that it inhibited the formation of 4，-，6- and 7-hydroxywarfarin significantly 
at }j.g/ml level. In addition, it was believed that active ingredients for the inhibition of 
the C Y P activity were contained in this ethanolic extract because no significant 
effect was found in the aqueous extract. This indicates that tanshinones may be 
affecting different C Y P isoforms in the wrafarin metabolism. The effects of 
tanshinone I，IIA and cryptotanshinone on warfarin metabolism showed that these 
compounds had different inhibitory effects on the formation of 4,-，6- and 7-
hydroxywarfarin, suggesting they may affect individual C Y P isoforms differently in 
the warfarin metabolism. 
Tanshinone I inhibited the formation of 4'- and 6-hydroxywarfarin significantly, 
however, it had no significant effect on the formation of 7-hydroxywarfarin in our 
studied concentration range. The result indicates that tanshinone I may inhibit 
CYP2B1 and CYP2C11 for catalyzing 4'-hydroxylation of warfarin, and CYPlAl 
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and CYP2C11 for catalyzing 6-hydroxylation of warfarin selectively. Our findings 
were comparable with the Ueng's study that tanshinone I inhibited the 7-
ethoxyresourufin 0-deethylation (EROD) and 7-methoxyresorufin 0-demethylation 
( M R O D ) activities, which are mainly catalyzed by CYPIA. In addition, it also 
inhibited the hydroxylation of tolbutamide, which is a CYP2C9 substrate by 22% at 
1 laM (Ueng et al., 2003), 
Tanshinone IIA is a major active ingredient of danshen that it weights about 1% of 
the dry weight of danshen (Wu et al., 1991). Tanshinone IIA (0.5 juM) selectively 
inhibited CYPlA-catalysed E R O D and M R O D activities in rat liver microsomes, 
without affecting other P450-catalysed oxidations such as benzo(a)pyrene, 
tolbutamide, chlorzoxazone and nifedipine, which are substrates for CYP2E1, 2C 
and 3A (Ueng et al., 2003). In addition, oral treatment of tanshinone IIA 
(75mg/kg/day, five days) caused induction of CYP1A2 in the rat liver microsomes 
which were Ah-receptor-dependence. However, our study found that tanshinone IIA 
just showed significant effects on the formation of 6- and 7-hydroxywarfarin, mainly 
catalyzed by CYPlAl and CYP2C6 at 135.92 |LIM. Besides, no effect was found on 
the formation of 4‘ -hydroxywarfarin. 
Cryptotanshinone inhibited the formation of 4,-, 6- and 7-hydroxywarfarin 
significantly by at least 70% at 539.61 compared to the control. 
Cryptotanshinone was much potent than tanshinone I and IIA. The Lineweaver-Burk 
plots indicate that cryptotanshinone is a competitive inhibitor for warfarin 
metabolism. It was confirmed by the good linearity obtained on the secondary plot 
(Km/Vmax against inhibitor concentration). This means that cryptotanshinone may be 
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a substrate for rat C Y P enzymes (CYPlAl, CYP2B6 and CYP2C11), competing the 
same catalytic site with warfarin and preventing warfarin for binding the catalytic 
site such that less hydroxywarfarin metabolites were produced. Like tanshinone I, 
cryptotanshinone was reported to inhibit E R O D and M R O D activities and 
tolbutamide oxidation without affecting other P450-mediated oxidations (Ueng et al., 
2003). 
There are many possible mechanisms for inhibition of P450-mediated oxidation. The 
most common type of inhibition is reversible inhibition, including competitive, non-
competitive, uncompetitive and mixed inhibition, which the substrate can bind to the 
enzymes and affect its catalytic activity reversibly. From our result, cryptotanshinone 
showed a linear competitive inhibition. However, it is difficult to assess the mode of 
inhibition for tanshinone I and IIA which may involve more than one type of 
inhibition mechanisms. Tanshinone I and IIA may affect other steps involved in the 
P450 catalytic cycles, such as oxidation and reduction of haem iron, NADPH-P450 
reductase and cytochrome bs activities. More studies need to be carried out to 
understand how danshen may affect these catalytic processes. 
In conclusion, danshen extract and some ethanolic components have shown an 
inhibitory effect on warfarin metabolism in the rat in vitro, suggesting that the 
danshen-warfarin interactions previously observed may have an underlying 
metabolic basis. The extent of inhibition of danshen extract, aqueous extract, 
ethanolic extract and the isolated constituents was quite different, so was the possible 
mode(s) of inhibition. However, it would seem quite certain the aqueous extract of 
danshen has the least potential for causing pharmacokinetic interactions in affecting 
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the C Y P enzymes. Compounds in the ethanolic fraction may be the potential C Y P 
inhibitors in man. As inhibition was observed at ^ M level, this means that only small 
amount of these compounds absorbed in the body may exert a significant effect on 




Effects of danshen extract and some of its active 
ingredients on warfarin metabolism in human pooled liver 
microsomes and the human CYP2C9 isoform 
3.1 Introduction 
Cytochrome P450 (CYP) is the major group of enzyme responsible for the 
metabolism of warfarin in human (Kaminsky et aL, 1984). R-warfarin is metabolized 
primarily by C Y P 1 A 2 to 6- and 8- (R)-hydroxywarfarin, by C Y P 3 A 4 to lO-(R)-
hydroxywarfarin, whereas S-warfarin is metabolized by CYP2C9 to 7- (S)-
hydroxywarfarin (Yamazaki & Shimada，1997). Due to the broad substrate 
specificity of CYP, warfarin-drug interactions are commonly observed in clinics that 
are largely due to the alteration the C Y P activity by coadministrated drugs. 
Experimental models are useful for understanding the molecular interaction 
mechanisms and avoiding the potential interactions. The most commonly used in 
vitro models are animal liver microsomes and recombinant human enzyme expressed 
in viral or microbial host systems. Besides, the simple incubation and analytical 
system provide rapid, predictive and straightforward in vitro tools to study the 
interaction of metabolism for human. Inhibition of enzyme activity can be reflected 
directly by the decrease the formation of metabolites. 
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In the previous chapter (Chapter 2), the effects of danshen extract and some of its 
active ingredients on warfarin metabolism was studied in rat liver microsomes. It was 
found the that danshen extract, the ethanolic extract of danshen, tanshinone I, 
tanshinone IIA and cryptotanshinone showed different inhibitory effects on the 
formation of warfarin metabolites. Although rat liver microsomes was a commonly 
used in vitro model, they do not always have the same copy of C Y P as human. Rat 
was reported to be a good metabolism model for C Y P 1 A 2 and CYP2E1 which they 
have similar typical substrates and metabolic activities as human (Shimada et al., 
1997) However, CYP3A4, which is the most abundant C Y P form in human, are 
absent in rat and the rat orthologous CYP3A1 is not induced by typical C Y P 3 A 
inducer, such as rifampicine (Lu & Li, 2001) Besides, another important human drug 
metabolizing enzyme C Y P 2 D 6 is represented by an orthologous CYP2D1 in rats 
However, they show different mechanisms in metabolism (Nedelcheva & Gut, 1994). 
Therefore, it is necessary to compare our experimental result obtained from rat liver 
microsomes with the human liver microsomes to see whether rat microsomes is a 
good animal model for predicting warfarin-drug interactions in human. 
Pooled human liver microsomes and human lymphoblast expressed CYP2C9 were 
used in the study. There are some advantages for using pooled human liver 
microsomes in the inhibition experiment. Firstly, pooled human liver microsomes 
contains the whole copy of human C Y P isoforms for drug metabolism. Also，the 
amount of NADPH-cytochrome P450 reductase, cytochrome b5 and the type of 
lipids in human liver microsomes are the same as intact liver. Besides, the use of 
pooled human liver microsomes can find out the net effect of inhibitors on C Y P 
activity. For further investigation of interaction mechanisms, C Y P isoforms can be 
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used that this system is simple and the effect of drug on the particular C Y P isoform 
can be known directly. As S-warfarin is mainly metabolized by CYP2C9 into 7-(S)-
hydroxywarfarin, human lymphoblast expressed CYP2C9 was used to determine 




3.2 Materials and methods 
3.2.1 Chemicals and reagents 
Human lymphoblast expressed CYP2C9 (Arg) and pooled human liver microsomes 
were purchased from Gentest (Wobum, M A , USA). Danshen extract was donated by 
Winsor Health Products Limited (Hong Kong). Tanshinone I, tanshinone IIA, 
cryptotanshinone was purchased from Chengdu Congon Bio-tech Co., Ltd (China). 
Warfarin, 4，-, 6-, 7-, 8-, 10-hydroxywarfarin, 7-ethoxycoumarin, P-nicotinamide 
adenine dinucleotide phosphate (NADP), D-glucose 6-phosphate (G6P) and glucose 
6-phosphate dehydrogenase, were obtained from Sigma Chemical Co. (St. Louis, 
M O , USA). Ammonia and magnesium chloride were supplied by Merck (Darmstadt, 
FRG). Acetic acid was obtained from Schartau Chemie (USA). Sodium hydroxide 
was purchased from B D H Laboratory Supplies (Poole, England). Acetronitrile and 
methanol (both H P L C grade) were supplied by Mallinckrodt Baker Inc. (Paris, 
Kentucky, USA). Ethyl acetate was purchased from Fluka Chemicals (Buchs, 
Switzerland). 
3.2.2 Incubation conditions for warfarin metabolism 
Pooled human liver microsomes (25 jul of 20 mg/ml, 2 mg/ml) and human 
lymphoblast expressed CYP2C9 (25 \jil of 10 mg/ml, 1 mg/ml) were added for 
metabolism of racemic warfarin and S-warfarin, respectively. The protein content of 
human microsomes was used as described in the data sheets supplied by 
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manufacturer. Microsomes was stored at -70。C and it was thawed rapidly in a 37°C 
water bath before use. 
The incubation mixture contains substrate (warfarin or S-warfarin) (15.4 ixl of 100 
l^g/ml, 20 ^ iM), N A D P (25 )al of 10 mg/ml, 0.66 mM)，G6P (25 j^l of 10 mg/ml, 1.64 
m M ) and magnesium chloride (17 of 10 mg/ml, 5 m M ) . It was made up by 
Tris/KCl buffer (0.05 M at p H 7.4) to final volume 250 jil. The reaction was initiated 
by adding G6P dehydroagenase (5 /xl of 20 units/ml, 0.1 units) and the whole mixture 
was incubated at 37 °C for 1 hour, with shaking on a rotating apparatus of 900 rpm. 
The reaction was stopped by adding 0.5 ml of ice-cold acetronitrile and the mixture 
was centrifuged at 13,000 rpm for 10 minutes to precipitate the microsomal protein. 
0.5 ml ethyl acetate was added to the supernatant with 7-ethoxycoumarin (10 \i\ of 
100 |ig/ml, 2.63 pmoles) as an internal standard. This mixture was shaken for 30 
minutes at 1400 rpm and then centrifuged at 13,000 rpm for 10 minutes. The upper 
ethyl acetate layer was collected and evaporated with a gentle stream of nitrogen gas 
at 40 °C. The residue was dissolved by 60 ]il of methanol and 50 \il of sample was 
injected to the H P L C system for analysis. 
3.2.3 Effects of danshen extract and its components on warfarin metabolism in 
vitro 
The effects of danshen extract, aqueous extract, ethanolic extract, tanshinone I, 
tanshinone IIA and cryptotanshinone, on warfarin metabolism were investigated by 
using human liver microsomes or human lymphoblast expressed CYP2C9. Danshen 
extract and aqueous extract of danshen were dissolved in water as stock solution. The 
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concentration range for danshen extract and aqueous extract used in the study was 
0.2 to 1.0 mg/ml. For the ethanolic extract of danshen, tanshinone I, tanshinone IIA 
and cryptotanshinone, they were dissolved in D M S O and made up to desired 
concentrations. In each incubation sample, 2 jiil of danshen component was added 
and 2 ixl of D M S O was added to the control. The final concentration of D M S O in the 
whole mixture was smaller than 1%. The concentration range for the ethanolic 
extract was 1.25 to 20 [xg/ml and three isolated lipid-soluble components was also 
1.25 to 20 |ig/ml (4 to 68 |liM) (Table 3.1). 
i^g/ml 1.25 2.5 5 10 20 
Tanshinone I ( M W 276.3) 4.52 9.05 18.10 36.19 72.38 
Tanshinone IIA ( M W 294.3) 4.25 8.50 16.99 33.98 67.96 
Cryptotanshinone ( M W 296.4) 4.22 8.44 16.87 33.74 67.48 
Table 3.1 Conversion of concentration units (jug/ml to |iM) for danshen isolated 
constituents. M W stands for molecular weight. 
3.2.4 High Pressure Liquid Chromatography (HPLC) analysis 
The H P L C system for quantification of warfarin and its metabolites was same as 
described in Chapter 2. The stationary phase was a reversed-phase C-8 column 
(Agilent Zorbax Eclipse XDB-C8, 150 m m x 4.6 mm). The mobile phase was a 
mixture of 1.5% acetic acid (pH 4.72, adjusted by concentrated ammonia) and 
acetronitrile, which was eluted by gradient mode with flow rate Iml/min. 
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3.2.5 Calibration curves 
Eight concentrations for analytes were used to set up the calibration curves, ranging 
from 0.4 to 8 /xg/ml for warfarin and 0.01 to 0.4 /xg/ml for warfarin metabolites. 
Warfarin and its metabolites, with 7-ethoxywarfarin as internal standard, were spiked 
into Tris/KCl buffer. The total final volume was 250 |il and the mixture was treated 
as the entire sample preparation procedures. After obtaining H P L C chromatograph, 
the peak height ratio (peak height of analyte/peak height of internal standard) was 
calculated and plotted against its concentration. The linearity of standard curve was 
tested by liner regression method and R-squared values were greater than 0.99 for all 
analytes. 
3.2.6 Data analysis 
The data was analyzed by Student's t-test in the Statview version 9.0 (Abacus 
Concepts, USA). There was statistical significant difference between group and 
control if P<0.05. The IC20 value was found by visual analysis on the percentage of 
control activity against the concentration of inhibitor, which was the concentration of 
inhibitor required to achieve 20% of inhibition. 
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3.3 Results 
3.3.1 Effects of danshen extract and its components on warfarin metabolism by 
using human pooled liver microsomes 
Due to the detection limit of H P L C system, only the concentration of 7-
hydroxywarfarin, which was the major metabolites of warfarin in human liver 
microsomes, was detectable and compared throughout this study. It was found that 
danshen extract (0.4 to 1 mg/ml) reduced the formation of 7-hyroxywarfarin 
significantly from 26 to 73% (Fig 3.1). However, the aqueous extract was much less 
potent inhibitor that the concentration of 7-hydroxywarfarin just reduced from 11 to 
26% (Fig 3.2). The IC20 values for danshen extract and aqueous extract on the 
formation of 7-hydroxywarfarin was 0.22 mg/ml and 0.78 mg/ml, respectively (Table 
3.2). Ethanolic extract was much potent than danshen extract and aqueous extract. It 
inhibited the formation of 7-hydroxywarfarin significantly at 5 to 20 |j.g/ml from 20 
to 54% (Fig 3.3). 
Among the isolated compounds, tanshinone I (4.52 to 72.39 |LIM) was the most potent 
that it decreased the formation of 7-hydroxyarfarin significantly from 90% to 34% 
(Fig 3.4). Cryptotanshinone (4.22 to 67.48 jiM) also inhibited the metabolism in a 
dose-dependent manner from 75 to 44% (Fig 3.6). However, the inhibitory effect of 
tanshinone IIA just increased with less extent from at 4.25 to 67.96 |LIM that the 
percentage inhibition was 25 to 37 % (Fig 3.5). The potency of danshen extract and 
its components to inhibit warfarin metabolism in pooled human liver microsomes 
was compared using their IC20 values as shown in Table 3.2. 
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日 I I l 
^ ^B ^ m ^ta 
l U l l i 
0.00 0.20 0.40 0.60 0.80 1.00 
Danshen extract (mg/ml) 
Fig 3.1 Effects of danshen extract on the formation of 7-hydroxywarfarin by using 
pooled human liver microsomes. Values are mean 士 S E M , *p<0.05，**p<0.01 and 
***p<0.001 compared to control (n=3). 
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0.12- ^ f c ^ ^ 
i l l 
0.00 0.20 0.40 0.60 0.80 1.00 
Aqueous extract of danshen (mg/ml) 
Fig 3.2 Effects of aqueous extract of danshen on the formation of 7-hydroxywarfarin 
by using pooled human liver microsomes.Values are mean 士 S E M , *p<0.05, 
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Ethanolic extract of danshen (jig/ml) 
Fig 3.3 Effects of ethanolic extract of danshen on the formation of 7-
hydroxywarfarin by using pooled human liver microsomes. Values are mean 士 SEM, 
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Tanshinone I OM) 
Fig 3.4 Effects of tanshinone I on the formation of 7-hydroxywarfarin by using 
pooled human liver microsomes. Values are mean 士 S E M , *p<0.05, **p<0.01 and 
***p<0.001 compared to control (n=3). 
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l l l l l i i 
0.00 4.25 8.50 16.99 33.98 67.96 
Tanshinone IIA (|iM) 
Fig 3.5 Effects of tanshinone IIA on the formation of 7-hydroxywarfarin by using 
pooled human liver microsomes. Values are mean 士 S E M , *p<0.05, **p<0.01 and 
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0.00 4.22 8.44 16.87 33.74 67.48 
Cryptotanshinone (|iM) 
Fig 3.6 Effects of cryptotanshinone on the formation of 7-hydroxywarfarin by using 
pooled human liver microsomes. Values are mean 士 SEM, *p<0.05, **p<0.01 and 
***p<0.001 compared to control (n=3. 
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3.3.2 Effects of danshen extract and its components on S-warfarin metabolism 
by using human lymphoblast CYP2C9 isoform 
S-warfarin is mainly metabolized by CYP2C9 to yield 6- and 7-hydroxywarfarin. 
The formation of 7-hydroxywarfarin is usually a marker for the activity of CYP2C9 
in man. Danshen extract (1 mg/ml) inhibited the formation of 7-hydroxywarfarin 
significantly by 95% (Fig 3.7). The aqueous extract (0.4 to 1 mg/ml) decreased the 
wafarin metabolism significantly from 90 to 52% (Fig 3.8). Therefore, danshen 
extract was more effective to inhibit the CYP2C9 isoform. Ethanolic extract (1.25 to 
20 |ag/ml) was found to reduce the 7-hydroxywarfarin concentration significantly 
from 83 to 54% (Fig 3.9). 
Tanshinone I was the most potent inhibitor for CYP2C9 isoform. At 4.52 to 72.39 
]iM, it reduced the formation of 7-hydroxywarfarin from 75 to 52% (Fig 3.10). 
However, cryptotanshinone (4.22 to 67.48 )iM) decreased the formation from 84 to 
62% (Fig 3.11). Tanshinone IIA (4.25 to 67.96 ^ M ) was the least potent that the 
concentration of 7-hydroxywarfarin decreased from 84 to 76% (Fig 3.12). All their 
IC20 values were shown on Table 3.2 
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Pooled human liver Human CYP2C9 isoform 
IC20 
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Tanshinone IIA (|LIM) 8.0 11.0 
Cryptotanshinone (|LIM) 3.0 5.5 
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Danshen extract (mg/ml) 
Fig 3.7 Effects of danshen extract on the formation of 7-hydroxywarfarin by using 
human CYP2C9 isoform.Values are mean 士 S E M , *p<0.05, **p<0.01 and 
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Aqueous extract of danshen (mg/ml) 
Fig 3.8 Effects of aqueous extract of danshen on the formation of 7-hydroxywarfarin 
by using human CYP2C9 isoform. Values are mean 士 SEM，*p<0.05, **p<0.01 and 
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0 1.25 2.5 5 10 20 
Ethanolic extract of danshen (|ig/ml) 
Fig 3.9 Effects of ethanolic extract of danshen on the formation of 7-
hydroxywarfarin by using human CYP2C9 isoform. Values are mean 士 SEM, 
*p<0.05, **p<0.01 and ***p<0.001 compared to control (n-3). 
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Tanshinone I (|iM) 
Fig 3.10 Effects of tanshinone I on the formation of 7-hydroxywarfarin by using 
human CYP2C9 isoform.Values are mean 士 S E M , *p<0.05, **p<0.01 and 
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Fig 3.11 Effects of tanshinone IIA on the formation of 7-hydroxywarfarin by using 
human CYP2C9 isoform.Values are mean 士 SEM，*p<0.05, **p<0.01 and 




I 圖 圖 囊 臺 千 * � 
^ ^ m ^ m ^ m 
o ^^^^ ^^^^ ^^^^ u ^ ^ ^ ^ ^ ^ ^ ^ i^^^m ？ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^^^^ ^^^^ t^^^m 
r _ I _ • I • 
0.00 4.22 8.44 16.87 33.74 67.48 
Cryptotanahsinone (|iM) 
Fig 3.12 Effects of cryptotanshinone on the formation of 7-hydroxywarfarin by using 
human CYP2C9 isoform. Values are mean 士 S E M , *p<0.05, **p<0.01 and 




In the previous chapter, danshen extract and its components showed different degrees 
of inhibition on warfarin metabolism in rat liver microsomes. Although rat liver 
microsomes is commonly used as an in vitro tool for screening the drug interactions, 
it remains controversial to extrapolate to the rat studies in predicting human 
metabolism, involving CYP1A2 and 2E1 (Shimada et al., 1997). However, warfarin 
is mainly metabolized by several C Y P isoforms, which are CYP1A2, CYP2C9 and 
CYP3A4. Therefore, the data obtained from rat microsomes may not be appropriate 
to predict the situation in man. Studies by using human liver microsomes will 
provide additional information in the species difference between human and rat for 
the danshen-warfarin interactions. 
The effects of danshen extract and its components on pooled human liver 
microsomes and human lymphoblast CYP2C9 isoform was evaluated in this chapter, 
by measuring the formation of warfarin metabolites. The result obtained in the 
CYP2C9 isoform study was agreeable with the pooled human liver microsomes 
studies, but with different degrees of inhibition. Danshen extract was found to inhibit 
the CYP2C9 isoform in a greater extent than pooled human microsomes, with IC20 
values 0.12 and 0.32 mg/ml, respectively. Besides, aqueous and ethanolic extracts 
also inhibited the activity of CYP2C9 more significantly compared to pooled human 
microsomes. Their IC20 values were shown on Table 3.1. Tanshinone I was the most 
potent inhibitor on the formation of 7-hydroxywarfarin in both pooled human liver 
microsomes and human CYP2C9 isoform studies with the same IC20 value 3.0 jiiM. 
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For tanshinone IIA and cryptotanshinone, they also inhibited the pooled human liver 
microsomes more than CYP2C9 isoforms. 
From the result, it seems that danshen extract and aqueous extract affect the activity 
CYP2C9 isoform predominantly. While tanshinone I, IIA and cryptotanshinone 
showed greater degree of inhibition on pooled human liver microsomes. As danshen 
extract and its components have shown inhibition on the formation of 7-
hydroxywarfarin, this suggests that the CYP2C9 mediated warfarin metabolism has 
been affected. Danshen extract and its components maybe a substrate for CYP2C9 
isoform or can bind to it in order to alter its catalytic activity. However, the mode of 
inhibition should be further investigated. The result also implies that danshen may 
have great potential to interact with other CYP2C9 substrate, like antipyrine, 
tolbutamide, diclofenac and carbamazepine. In addition, danshen may also inhibit 
other CYP-mediated warfarin metabolism pathways (CYP1A2 and CYP3A4), 
however, this cannot be verified in our study because the formation of 4，- and 6-
hydroxywarfarin was below our detection limit. 
Strictly speaking, warfarin is not a good model probe substrate for drug interaction 
study as it is metabolized by several C Y P isoforms. However, we have interest to 
study on it because warfarin-danshen interactions were reported in clinics. Other 
more specific probe substrates can be used to assess the particular C Y P isoform 
activity. For examples, the probe substrates for CYP1A2 are 7-methoxyresourfin and 




The effect of tanshinone IIA on monoxygenase activities in human liver microsomes 
and bicistronic human C Y P l A l and C Y P 1 A 2 was studied (Ueng et al., 2003). 
Tanshinone IIA (0.5 |iM) inhibited the 7-ethoxyresourfin 0-deethylation (EROD) 
and 7-methoxyresurfin 0-demethylation ( M R O D ) activities in human by 52 and 47%, 
which are mainly catalyzed by CYPlAl and CYP1A2. The IC50 of tanshinone IIA 
for C Y P l A l activity was 49 times higher than CYP1A2. The concentration of 
tanshinone IIA ranged from 0.2 to 1 jiM, which was much lower than our study (4.25 
to 67.96 |j,M). This difference may due to different incubation conditions were used. 
Tolbutamide hydroxylation was not inhibited by tanshinone IIA at 0.5 iiM (Ueng et 
al., 2003). This was consistent with our findings in this study that tanshinone IIA did 
not inhibit the formation of 7-hydroxywarfarin significantly at 4.25 to 8.50 ^iM. 
Furthermore, 0.5 |LIM tanshinone IIA was found to possess no inhibition of 
benzo(a)pyrene (CYP2C substrate), chloroxazone (CYP2E1 substrate) and nifedipine 
(CYP3A substrate). However, the effect of danshen extract and its components on 
these isoforms cannot be verified in our study because of the sensitivity of H P L C 
system. 
Compared to the rat liver microsomes study, it was found that the results were quite 
agreeable with the human microsomes study that danshen extract and its components 
showed inhibition on the warfarin metabolism. However, it was interesting to note 
that the aqueous extract inhibited the formation of 7-hydroxywarfarin in human liver 
micrsomes but not in the rat microsomes. This indicates that the rat microsomes data 
may not extrapolate correctly to the human situation and different models should be 
applied to give a better extrapolation. 
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To conclude, danshen extract and its components decreased both the activity of 
pooled human liver microsomes and human lymphoblast expressed CYP2C9 to 
different extent. Ethanolic extract was more effective to inhibit the warfarin 
metabolism than the danshen extract. In addition, aqueous fraction was found to 
inhibit the human microsomes but had no effect on the rat microsome study. As there 
is a risk for danshen and warfarin to cause metabolic interactions in man, clinicians 
should advice their patients that do not consume danshen when receiving warfarin 




Effects of acute and subchonic pretreatment of danshen 
extract on the pharmacokinetics of warfarin in the rats in 
vivo 
4.1 Introduction 
Exaggerated adverse effects of warfarin were reported in clinics when patients took 
warfarin and danshen cocurrently (Chan, 2001). The bleeding complications and 
increased INR in patients suggest that danshen may have affected the 
pharmacokinetic and pharmacodynamic properties of warfarin. In single dose and 
steady state studies, it was found that danshen extract significant increased the 
plasma concentration of R- and S- warfarin and the prothrombin time in the rats 
(Chan et al., 1995). The result was similar to that observed in patients and may 
explain the underlying mechanism(s) of the over-anticoagulation. However, the 
mechanism(s) of this warfarin-danshen interactions remains uncertain. 
Many drugs have been reported to interact with warfarin by either induction or 
inhibition of cytochrome P450, which are among the major cause of pharmacokinetic 
warfarin-drug interactions. In Chapter 2 and 3, rat and human liver microsomes have 
been used as in vitro models to study the metabolism of warfarin in the presence of 
danshen extract and other danshen components. It was found that danshen extract 
and its components showed different inhibitory effects on warfarin metabolism, 
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possibly due to different levels of inhibition of C Y P isoforms. These in vitro models 
provide a rapid screening for studying the inhibition of drug metabolizing enzymes. 
However, in vivo model is also necessary to give more information about the drug 
interactions because an animal is a complex physiology model that the overall 
pharmacokinetics of a drug is determined by absorption, distribution, metabolism 
and excretion. In addition, some C Y P inhibitors may also inhibit the activity of 
intestinal C Y P isoforms by modifying the P-glycoprotein (Hall et al., 1999). 
Our laboratory studied the effects of danshen extract on the pharmacokinetics of 
warfaim in the rats before, but the formation of warfarin metabolites were not 
measured (Chan et al., 1995). In the present study, rats were pretreated with danshen 
extract acutely for one day or sub-chronically for three days to see their effects on the 
pharmacokinetics of warfarin. Besides, H P L C system was set up to measure the 
warfarin metabolites that the formation of warfarin metabolites is a good indicator to 
know whether danshen extract affect the warfarin metabolism by induction or 
inhibition in vivo. The major warfarin metabolites formed in the rats in vivo have 
little difference from the in vitro. R-warfarin is metabolized predominately to 7-
hydroxywarfarin whereas S-warfarin is metabolized to form 4，- and 7-
hydroxywarfarin in vivo. However, R-warfarin is metabolized into mainly 6- and 7-
hydroxywarfarin, wherease S-warfarin is metabolized into 4,-, 6- and 7-
hydroxywarfarin in rat liver microsomes (Fasco et al., 1982). The blood samples 
were collected for 48 hours after warfarin post dose and analysed by HPLC. The 
pharmacokintic parameters for warfarin were compared to the control in order to 
investigate how danshen extract affect the overall pharmacokinetic profile of 
warfarin in the rats. In addition, the formation of warfarin metabolites was also 
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compared to see whether danshen extract has any effects on the warfarin metabolism 
in vivo. 
In the steady state study, the change in plasma warfarin concentration after danshen 
treatment gives important information about the effect of danshen extract on warfarin 
metabolism. It was because absorption and distribution phases become stable after 
the plasma warfarin concentration reaches the steady state. Therefore, the clearance 
of warfarin depends mainly on the hepatic blood flow and the activity of drug 
metabolizing enzymes. In addition, the formation of warfarin metabolites can 
confirm whether the warfarin metabolism is really being affected. Therefore, the 
H P L C system was set up to measure the warfarin metabolites which were not 
measured in the Chan's study (Chan et al., 1995). Finally, the result from the steady 
state study may extrapolate to patients who have taken danshen after receiving a 
period of warfarin treatment. 
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4.2 Materials and methods 
4.2.1 Chemicals and reagents 
Danshen extract was characterized and donated by Winsor Health Products Ltd. 
(Hong Kong). Warfarin, 4，-, 6-, 7-, 8-, 10-hydroxywarfarin, 7-ethoxycoumarin and 
cimetidine were obtained from Sigma Chemical Co. (St Louis, M O , USA). 
Phenobarbitone was purchased from Universal Pharmaceutical Lab., Limited (Hong 
Kong). Ammonia and diethyl ether was purchased from Merck (Darmstadt, FRG). 
Acetic acid was supplied by Schartau Chemie (USA). Acetronitrile and methanol 
were purchased from Mallinckrodt Baker Inc. (Paris, Kentucky, USA). Hydrochloric 
acid was purchased from B D H (UK). 
4.2.2 Animals 
Male Sprague Dawley rats (250-280 g) were supplied by the Laboratory Animal 
Service Centre, The Chinese University of Hong Kong. Animals were housed with 
alternating 12-hr light-dark cycles, with free access to standard laboratory food and 
tap water. In the single dose warfarin study, animals were fasted overnight before 
oral warfarin administration and food was resumed 4 hours after post dose. Free 
access to food and water was allowed for the rats in the steady state study. 
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4.2.3 Effects of acute danshen extract pretreatment on the pharmacokinetics of 
warfarin 
The rats were pretreated with danshen extract intraperitoneally twice daily (9 am and 
5 pm) at 200, 300 and 400 mg/kg/twice daily for a single day (dose volume 2 ml/kg). 
The control rats received an equal volume of saline. A single oral dose of warfarin 
(2mg/kg) (dose volume 2ml/kg) was administered in the morning and blood samples 
were obtained at 2, 4, 8, 12, 24, 36 and 48 hours. For blood sampling, the rats were 
weighed and anaesthetized by diethyl ether. Blood samples (0.5 ml) were collected 
from the tail artery. The rats were allowed to recover, with free access to food and 
water after each blood sampling. The plasma was separated immediately by 
centrifugation at 13,000 rpm for 10 minutes and was stored at -20。C before H P L C 
analysis. 
4.2.4 Effects of subchronic danshen extract pretreatment on the 
pharmacokinetics of warfarin 
The rats were pretreated with danshen extract intraperitoneally twice daily (9 am and 
5 pm) at 200, 300 and 400 mg/kg/twice daily (dose volume 2 ml/kg) for consecutive 
three days. The control rats received an equal volume of saline. After three days of 
danshen pretreatment, the rats were given a single dose of warfarin (2mg/kg) (dose 
volume 2 ml/kg) at the morning and blood samples were collected at 2，4, 8, 12, 24, 
36 and 48 hours for pharmacokinetic analysis. The blood sampling method was same 
as described in 4.2.3. 
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The rats were pretreated with cimetidine intraperitoneally at 60 mg/kg (dose volume 
2 ml/kg) as negative control for enzyme inhibition one hour before oral 
administration of warfarin at the morning. Besides, the rats were pretreated with 
phenobarbitone intraperitoneally at 40 mg/kg (2ml/kg) for three days as positive 
control for enzyme induction. Afterwards, a single dose of warfarin (2 mg/kg) (dose 
volume 2ml/kg) was given to the rats orally and the pharmacokinetics of warfarin 
was studied at 2, 4, 8, 12, 24, 36 and 48 hours. The blood sampling method was same 
as described in 4.3.2. 
4.2.5 Steady state warfarin study 
The rats were treated with a single oral dose of warfarin at 0.2 mg/kg/day (dose 
volume 2ml/kg) in the afternoon for consecutive eight days. The warfarin steady 
state was achieved after five days of treatment. On day five to day eight of the study, 
danshen extract was administrated orally to each rat twice daily at 2 g/kg (dose 
volume 2ml/kg), before or after four hours of oral warfarin administration. Blood 
samples were collected each day for H P L C analysis. 
4.2.6 Sample extraction 
7-ethoxycoumarin (6 |LI1 of 50 |Lig/ml, 1.58 pmoles in methanol) was added to 150 |Lil 
of plasma for sample extraction. 0.5 ml of hydrochloric acid (2M) was added to 
precipitate the plasma protein and 5 ml of diethyl ether was added for extraction of 
warfarin and its metabolites. The mixture was shaken at 1,400 rpm for 30 minutes in 
a rotatary shaker and subsequently centrifuged at 13,000 xg for 10 minutes. The 
diethyl ether layer was collected and evaporated to dryness at 45 under a gentle 
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Stream of nitrogen. The dry residue was redissolved in 60 ]il of methanol and 50 jul 
of sample was injected to the H P L C system. 
4.2.7 High Pressure Liquid Chromatography (HPLC) analysis 
The H P L C system for analysis of warfarin and its metabolites was as described in 
Chapter 2, which was a modification method from Fasco (Fasco et al., 1977). The 
stationary phase was a reversed-phase C-8 column (Agilent Zorbax Eclipse XDB-C8, 
150 m m X 4.6 m m ) and the mobile phase was a mixture of 1.5% acetic acid (pH 4.72, 
adjusted by concentrated ammonia) and acetronitrile. All experiments were 
performed at ambient temperature. The retention time for 4，- and 7-hydroxywarfarin, 
7-ethoxycoumarin and warfarin were about 8.3, 8.7, 10.0 and 10.5 minutes 
4.2.8 Calibration curve 
Calibration curve was constructed by spiking a known amount of warfarin (1.67 to 
33.33 /xg/ml) and warfarin metabolites (0.17 to 3.33 /ig/ml) to the blank rat plasma, 
together with 7-ethoxycoumarin as an internal standard. The mixture was then 
treated as the entire sample preparation procedures. After the H P L C analysis, the 
peak height ratio (peak height of analyte / peak height of internal standard) was 
calculated and plotted against the concentration. The linearity of the standard curve 
was tested by liner regression analysis and R-squared values for all analytes were 
greater than 0.98. 
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4.2.9 Data analysis 
The Microsoft program P K solution 2.0 (Dr. Farrier, D. S., Summit Research 
Services, Ashland, U S A ) was used to determine the pharmacokinetic parameters by 
non-compartmental method. It was assumed that warfarin is totally absorbed though 
oral administration, ti/2 is the time for concentration reduced by half. Cmax is the peak 
serum concentration, while Tmax is the time for observed the peak concentration. 
A U C O - 4 8 is the cumulative area under the warfarin concentration-time curve for 
experimental time points and AUCinfinity is the total area from time zero to infinity, 
which was estimated by using the linear trapezoidal approximation. Vd is the volume 
of distribution that defined as the volume of fluid required to contain the total 
amount of drug in the body. C L is the clearance of drug that determines the 
maintenance dose to achieve a desired concentration. 
Results were expressed as mean 土 standard error of the mean (SEM). The 
pharmacokinetic parameters of danshen treatment group and control were compared 
by Student's t-test in Statview version 9.0 (Abacus Concepts, USA). The A U C for 
each warfarin metabolites were calculated by using Prism (GraphPad Software, Inc. 
San Diego, CA, USA). The concentration of warfarin and its metabolites were 
compared for each time point by Student's t- test. A difference with P < 0.05 was 




4.3.1 Effects of acute danshen extract pretreatment on the pharmacokinetics of 
warfarin 
The concentration-time courses of warfarin, 4 ‘ -hydroxywarfarin and 7-
hydroxywarfarin after oral administration of warfarin in rats with or without single 
day danshen extract pretreatment were shown in the Fig 4.1, 4.2 and 4.3, respectively. 
The pharmacokinetic parameters of warfarin were shown in the Table 4.1. For 
danshen pretreated rats (200 mg/kg/twice daily), there were significant difference in 
the ti/2, AUCo to 48，AUCinfmity and C L compared with the controls. However, these 
results were not observed in higher danshen doses (300 and 400 mg/kg/twice daily). 
On the other hand, Cmax was significantly decreased from 25.50 to 17.80 and 18.35 
jag/ml in danshen treated rats 300 and 400 mg/kg/twice daily, respectively. In 
danshen treated rats 400 mg/kg/twice daily, tmax was also prolonged significantly 
from 2.5 to 7.67 hours. Besides, there was a gradual trend that the plasma warfarin 
concentration in the early time points was lowered with increasing dose of danshen 
(Fig 4.1). However, danshen extract did not affect the C L and Vd at in danshen 
treated rats at 300 and 400 mg/kg/twice daily. For the formation of warfarin 
metabolites, there was no significant different in A U C of 4‘-hydroxywarfarin and 7-
hydorxywarfarin at all doses. Their A U C values were shown in Table 4.4A. 
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Fig 4.5 Effects of sub chronic pretreatment of danshen extract on the f o r m a t i o n of 4'-
hydroxywarfarin. Results are mean 土 SEM of 6 rats. ***p<0.001, **p<0.01 and 
*p<0.05 when compared to control. 
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Fig 4.5 Effects of sub chronic pretreatment of danshen extract on the formation of 4'-
hydroxywarfarin. Results are mean 土 SEM of 6 rats. ***p<0.001, **p<0.01 and 
*p<0.05 when compared to control. 
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Fig 4.5 Effects of sub chronic pretreatment of danshen extract on the formation of 4'-
hydroxywarfarin. Results are mean 土 SEM of 6 rats. ***p<0.001, **p<0.01 and 




































































































































































































































































































































































































































































4.3.2 Effects of subchronic danshen extract pretreatment on the 
pharmacokinetics of warfarin 
For subchronic danshen extract pretreatment, the plasma concentration-time curves 
for warfarin and its metabolites were shown in Fig 4.4，4.5 and 4.6. There was no 
significant difference in the major pharmacokinetic parameter such as ti/2, A U C , CL, 
Vd in all doses of danshen extract used compared to the control, as shown on Table 
4.2. However, Cmax decreased significantly from 22.52 to 17.82 and 16.37 \xg/m\ in 
danshen treated rats 300 and 400 mg/kg/twice daily. In addition, tmax for danshen 
treated rats 400 mg/kg/day prolonged significantly from 2.83 to 5 hours. Like the 
acute danshen extract pretreatment study, the plasma warfarin concentration was also 
lowered in the early time points with higher dose of danshen extract (Fig 4.4). At 400 
mg/kg/twice daily, the A U C of 4,-hydroxywarfarin and 7-hydroxywarfarin decreased 
significantly by 52% and 33% when compared to the control, respectively. However, 
there was also significant difference for the A U C of 7-hydroxywarfarin at 300 
mg/kg/twice daily compared to the control (Table 4.4B). 
For positive control, the effects of cimetidine and phenobarbitone on the 
pharmacokinetic parameters of warfarin were shown on Fig 4.6 and Table 4.3. It was 
found that phenobabitone increased AUC o to 48, AUC infinity, Vd increased while the 
Cmax and C L decreased significantly. However, there was no significantly effect of 
cimetidine on the pharmacokinetic parameters of warfarin. For the formation of 
warfarin metabolites, phenobarbitone decreased the A U C of 4,-hydroxywarfarin 
significantly by 55%, while cimetidine decreased the A U C of 4‘-hydoxywarfarin and 
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Fig 4.4 Effects of subchronic pretreatment of danshen extract on the 
pharmacokinetics of warfarin. Results are mean 土 SEM of 6 rats. **氺p<0.001, 
**p<0.01 and *p<0.05 when compared to control. 
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Fig 4.5 Effects of sub chronic pretreatment of danshen extract on the formation of 4'-
hydroxywarfarin. Results are mean 土 SEM of 6 rats. ***p<0.001, **p<0.01 and 
*p<0.05 when compared to control. 
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Fig 4.5 Effects of sub chronic pretreatment of danshen extract on the formation of 4'-
hydroxywarfarin. Results are mean 土 SEM of 6 rats. ***p<0.001, **p<0.01 and 
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Fig 4.6 Effects of phenobabitone and cimetidine on the A) formation of 4'-
hy droxywarfarin, B) the formation of 7-hydroxywarfarin and C) the 
pharmacokinetics of warfarin. Results are mean 土 S E M of 6 rats. ***p<0.001, 




















































































































































































































































































































































































A) Acute danshen extract pretreatment study 
AUC (|ig hr/ml) 4'-hydroxyarfarin 7-hydroxywarfarin 
Control 27.33 ± 1.91 12.21 ±0.55 
200 mg/kg/twice daily 27.12 ±1.01 11.36 士 0.91 
300 mg/kg/twice daily 27.96 ± 1.86 12.11 土 0,70 
400 mg/kg/twice daily 27.26 ± 1.04 10.17 士 0.54 
B) Subchronic danshen extract pretreatment study 
AUC (jig hr/ml) 4'-hydroxyarfarm 7-hydroxywarfarin 
Control 27.37 ±2.76 13.29 ±0.87 
200 mg/kg/twice daily 24.72 ±0.76 8.86 ±0.35 
^ 3 0 0 mg/kg/twice daily 27.96 ± 1.86 14.57 ±0.96* 
400 mg/kg/twice daily 14.51 ± 0.97*** 8.86 ±0.35* 
C) Positive control 
AUC (jig hr/ml) 4'-hydroxyarfarin 7-hydroxywarfarin 
Control 31.66 ±2.65 13.31 ± 1.41 
Phenobabitone 14.11 ± 0.51*** 10.63 ±0.59 
Cimetidine 17.34 ± 1.54*** 8.31 ±0.48** 
Table 4.4: The area under curve (AUC) for the formation of 4‘-hydroxywarfarin and 
7-hydroxywarfarin in the A) acute danshen extract pretreatment study B) subchronic 
danshen extract pretreatment study C) positive control study, (n=6) Values are mean 
± SE M . ***p<0.001, **p<0.01 and *p<0.05 when compared to control 
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4.3.3 Steady state warfarin study 
The plasma warfarin concentration for each day was calculated and plotted against 
time (Fig 4.7). The steady state was obtained after day two of warfarin treatment, 
which was shown by no significant differences of warfarin concentration for day two 
to day five. On day five to day seven, oral danshen extract (2 g/kg/day) was 
administrated to the rats. There was an increase of plasma warfarin concentration in 
day six and day seven. However, the effect of danshen extract on the steady state of 
warfarin was not very obvious. After taking statistical analysis, only the warfarin 
concentration in day seven was found significantly difference from day three and day 
four. Besides, the average warfarin concentration increased significantly from day 
five to day seven, which was the danshen treatment period, from 0.66 士 0.15 to 0.81 





I ^ [ 
二 1.0-1 T 
ID 
3 0 . 8 - ^ ^ 丄 、 
I 
I 0.6- / T f 个 个 个 
o 0.4" F Oral danshen extract treatment 
fi / (2g/kg/day, twice daily) 
I V  
0=04 1 1 1 1 1 1 1 1 
0 1 2 3 4 5 6 7 8 
Days 
Fig 4.7. The plasma warfarin concentration in the steady state study (N二7). 





In Chapters 2 and 3, danshen extract and its components were found to inhibit 
warfarin metabolism in vitro in rat liver microsomes and human liver microsomes. 
Since in vitro studies only represent a relative simplified tool for studying 
metabolism, in vivo studies are necessary to confirm if the in vitro data may be 
extrapolated to the more complex situation in vivo. In this chapter, rats were used as 
an animal model for studying the effect of danshen extract on the pharmacokinetics 
of warfarin. Single dose and steady state studies were designed for different 
approaches. In the single dose study, the rats were either pretreated with danshen 
extract acutely for one day or subchroniclly for three days and warfarin was 
administered orally. The overall pharmacokinetics profile of warfarin was 
determined by absorption, distribution, metabolism and excretion. However, 
absorption and distribution phases are stable and can be discounted at steady state of 
warfarin. 
In the single dose acute pretreatment study, danshen extract (300 and 400 
mg/kg/twice daily) decreased Cmax significantly by 30% and 28%, respectively. 
Besides, danshen extract (400 mg/kg/twice daily) prolonged Tmax significantly by 
200%. Similar result was obtained in the subchronic pretreatment study that danshen 
extract (300 and 400 mg/kg/twice daily) reduced Cmax by 21 % and 27%, 
respectively. Besides, danshen extract (400 mg/kg/twice daily) increased Tmax 
increased significantly by 43%. This suggests that danshen extract may affect the 
warfarin concentration in the circulation system at early time points. 
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From the result of acute and subchronic studies, it was obvious that Cmax decreased 
while Tmax was prolonged significantly after danshen extract pretreatment. There are 
many possible mechanism(s) for danshen extract to affect the plasma warfarin 
concentration, such as, absorption, distribution, protein binding, metabolism and 
excretion. Delayed absorption may be due to of gastrointestinal motility and 
intestinal p H (Ilett et al., 1990). Danshen contains different active ingredients that 
may have large possibility to interact with the gut lumen and alter the motility of 
intestine. In addition, drug interactions in the gastrointestinal tract may be caused by 
direct enzyme induction or inhibition (Shen et al., 1997). This can alter the rate of 
drug absorption and the oral bioavailability significantly. However, the effects of 
danshen extract on intestinal P450 cannot be verified in this study. As absorption 
may be one of the possible mechanism(s) for danshen-warfarin interactions, the 
effects of danshen extract on the absorption of warfarin would be studied in Chapter 
5, using Caco-2 cells absorption model. 
From the in vitro studies, it was known that danshen extract inhibited the P450-
mediated warfarin metabolism both in man and rats. In this chapter, the subchronic 
danshen extract pretreatment (400 mg/kg/twice daily) decreased the AUC(o to 48) of 
4‘-hydroxywarfarin and 7-hydroxywarfarin significantly by 52 and 33%, respectively. 
This suggests that danshen extract may inhibit the warfarin metabolism in rats in vivo. 
In addition, there was significant decrease in the AUC(o to 12) of 4，- and 7-
hydroxywarfarin at danshen extract (400 mg/kg/twice daily) in both acute and 
subchronic studies, which indicates that the effect of inhibition may be more 
significant from 0 to 12 hours after warfarin post dose. However, another possibility 
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for the lowered formation of metabolites may be due to the delay of warfarin 
absorption thus less amount of warfarin is available for converting to metabolites. 
Our result of single dose study was quite different to the study by Chan (Chan et al, 
1995), which found that danshen extract increased the bioavailability of warfarin but 
decreased its clearance. In our study, it was found that danshen extract had no effect 
on ti/2, A U C , C L and Vd of warfarin in both acute and subchronic pretreatment. 
However, significant difference on these parameters was found on the rats acutely 
pretreated with danshen extract (200 mg/kg/twice daily), but this difference cannot 
be explained. 
Steady state study gives information about the metabolic interaction in vivo because 
absorption and distribution phases are not involved in the change of drug 
concentration after reaching steady state. Like the previous study by Chan, it was 
found that the plasma warfarin concentration significant increased during the 
danshen treatment period (Chan et al., 1995). The result indicated that danshen 
extract may inhibit the warfarin metabolism and decrease its clearance. However, the 
amount of metabolites cannot be measured due to the sensitivity limitation of H P L C 
system. Different warfarin dosages and the treatment periods were attempted but this 
also cannot produce enough metabolites for analysis. 
Apart from absorption and metabolism, danshen may affect the distribution of 
warfarin. Danshen extract was reported to moderately to strongly bind to the protein, 
mainly albumin. In addition, danshen extract can displace salicylate which is strongly 
protein bound to albumin (Gupta et al., 2002). This suggests that it also may displace 
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the warfarin from the site of albumin and increase its free concentration. However, 
active ingredients of danshen showed poor bioavailability and absorption, like, 
tanshinone IIA, magnesium lithospermate B (MLB) (Gupta et al,, 2002), which 
means that very low concentration of these compounds can enter the blood 
circulation and its protein binding effect may not be so significant to interfere the Vd 
of warfarin, which have showed no significant change in our danshen pretreatment 
study. Further investigations on the protein binding interactions between danshen and 
warfarin are necessary to confirm whether danshen can displace warfarin from 
albumin site significantly or not. 
From both single dose and steady state studies, we can conclude that danshen extract 
may affect the pharmacokinetic of warfarin by metabolic interaction. The decreased 
in Cmax and prolonged in Tmax found in the single dose rat study indicated that 
danshen extract may lower the warfarin concentration in man at the beginning of 
warfarin therapy. This means that repeated doses of warfarin may be necessary to 
achieve the desired plasma warfarin level so as to produce a desirable anticoagulant 
effect. For the steady state study, it mimics the situation when patients consume 
danshen during warfarin therapy. The result from rat study may extrapolate to man 
that danshen may elevate the plasma warfarin concentration and exaggerate the 
anticoagulant effect of warfarin in patients who taking danshen and warfarin 
cocurrently. This extrapolation is relevant to those clinical case reports that increased 




Effects of danshen extract on the absorption of warfarin by 
using Caco-2 cells model 
5.1 Introduction 
Danshen extract and some of its active components have been shown to inhibit 
CYP2C9 mediated warfarin metabolism in vitro in the rats (Chapter 2) and in human 
liver microsomes and human CYP2C9 isoform (Chapter 3). Further in vivo studies in 
the rats (Chapter 4) showed that when danshen extract was coadministered with 
warfarin, the plasma concentration of warfarin and the 4'- and 7-hydroxywarfarin 
decreased from 0 to 12 hours. This was in contrast to the steady-state study in which 
danshen extract was shown to increase the warfarin concentration over the time 
period studied. The effects may suggest that pharmacokinetic processes other than 
metabolism may have contributed to the danshen-warfarin interactions. Therefore, 
the effect of danshen extract on the absorption of warfarin was studied in Caco-2 
cells, which is one of the most widely used absorption model, for studying intestinal 
transport processes at molecular level (Artursson & Karlsson, 1991). 
Warfarin is administered orally and thus absorption phase in the intestine is involved 
before it reaches into blood circulation system. Warfarin has high bioavailability in 
human that >98% is absorbed mainly though passive diffusion in the small intestine. 
For passive diffusion, the drug diffuses through several intestinal barriers to the 
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blood capillaries by concentration gradient. The most significant barrier in the 
absorption process is the monolayer of epithelial cells. Besides, intestinal metabolism 
may be also involved in this monolayer. Caco-2 cells monolayer model possess many 
of properties of human epithelial cells, therefore, it is a very good in vitro tool to 
study the absorption or secretion of the drug. Permeability is a useful parameter to 
determine the extent of drug absorption. Any change in the permeability indicates 
that the drug absorption process is altered. Further investigations are necessary to 
determine the causes of absorption interaction how drug have affect the transport 
mechanisms in the Caco-2 cells. 
Caco-2 cells are derived from a human colorectal adenocarcinoma that it 
differentiates spontaneously into polarized monolayers under normal culture 
condition. The culture period for caco-2 cells is around 21 days for developing the 
intestinal characteristics, such as microvillous structure, hydrolysis enzymes, 
junctional complexes and carrier mediated transport systems for glucose, amino acid 
peptide and bile acids (Yamashita et al,, 2000). In addition, caco-2 cells exhibit 
similar structures and functions to the human small intestinal epithelium, thus it 
showed a good correlation between oral drug absorption in human (Artursson & 
Karlsson, 1991). 
This chapter describes a preliminary experiment in which the stability and viability 
of the Caco-2 cells were established in the presence of danshen extract, warfarin and 
their combined presence. More importantly, the effect of danshen extract on the 
permeability of warfarin was investigating. 
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5.2 Materials and methods 
5.2.1 Materials for Caco-2 cells culture experiment 
Warfarin was purchased from Sigma Chemical Co. (St Louis, M O , USA). Danshen 
extract was kindly donated by Winsor Health Products LTD. Caco-2 cells were 
obtained from the American Type Culture Collection (Rockville, MD). Cells from 
• • � 
passage number 39 to 41 were used for the transport experiment. Six-well transwell 
plates (0.4 /xm pore size, 4.71 cm�，polycarbonate filter, Co star 3410) were obtained 
from Coming Costar Co. (NY, USA). Dulbecoo's modified Eagle's medium 
(DMEM), fetal bovine serum (FBS), 0.05% Trypsin-EDTA, Penicillin-Streptomycin 
and non-essential amino acids were purchased from GibcoBRL Life & Technologies 
(USA). Phosphate buffer tablets were purchased from Sigma Chemical Co. (USA). 
Collagen type I was obtained from Sigma Chemical C O (USA). Sodium pyruvic was 
purchased from International Laboratory U S A . 
5.2.2 Preparation of Caco-2 monolayer 
Caco-2 cells were cultured in D M E M supplemented with 10% FBS and 1% of non-
essential amino acids at 37。C in an atmosphere of 5 % CO2 and 90% relative 
humidity. The cells were harvested with trypsin-EDTA and seeded on the Transwell 
⑧ inserts coated with a collagen layer at a density of 3 X 10^ cells/well. The culture 
medium was replaced for every 48 hours. After 21 days, the integrity of the Caco-2 
cells monolayer was checked by measuring the transepithelial electrical resistance 
(TEER) with an epithelial voltohmeter before and after the transport experiment. 
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5.2.3 High Pressure Liquid Chromatography (HPLC) analysis for warfarin 
The H P L C system was set up as described in Chapter 1, which was a modification 
from Fasco (Fasco et al., 1977). The retention time for ethoxycoumarin and warfarin 
were about 10 and 10.5 minutes, respectively. 
5.2.4 Calibration curve 
Calibration curve was constructed by spiking warfarin into PBS+ buffer (0.01 M ) to 
make up different concentrations, 5, 10, 25, 50, 11, 150, 200, 250 and 300 ^ iM at pH 
7.4. 50 of warfarin standard was mixed with 5 of ethoxycoumarin (1.31 pmoles, 
50 }ig/ml) as internal standard. 50 \i\ of sample was injected to the H P L C for analysis. 
The peak height ratio of warfarin to ethoxycoumarin was calculated and plotted 
against the standard warfarin concentration. The linearity of calibration curve was 
over 0.99 after performing liner regression. 
5.2.5 Stability test for warfarin and danshen extract 
The Caco-2 cells transport experiments were performed in phosphate buffered saline 
plus (PBS+) (0.01 M ) at pH 7.4. PBS+ was made up of a PBS tablet, magnesium 
chloride (80 1 M ) and calcium chloride (90 1 M ) in 200 ml of water. The pH 
of PBS+ was adjusted by phosphoric acid to pH 7.4, if necessary. 
The stability test was carried by incubating warfarin (50|LLM), which dissolved in 
PBS+, with or without danshen extract (1 mg/ml) in a water bath at 37°C for 90 
minutes. 50 of sample was withdrawn for every 15 minutes and mixed with 5 of 
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ethoxycoumarin (1.31 pmoles, 50 |Lig/ml). 50 |LI1 of sample was injected to the H P L C 
for analysis. The concentration of warfarin found in the sample was plotted against 
time to find out if any change in the concentration of warfarin in the time period. 
5.2.6 Toxicity test of danshen extract on Caco-2 cells 
Caco-2 cells were seeded in a 96-well plate at a density 5 X 10^ cells per well in 
D M E M culture medium. The cells were incubated for 24 hours before carrying M T T 
(3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyl tetrazolium bromide) test. The M T T test 
was used to determine the viability of cells. 
Danshen extract was dissolved and made up to 0.1, 0.25, 0.5, 1 and 2 mg/ml in PBS+. 
The medium in the wells was removed and replaced by the danshen extract solution. 
The plate was incubated for 1 hour at 37 °C. After the incubation, 20 of M T T 
(5mg/ml in PBS+) was added to each well and the plate was further incubated for 4 
hours at 37 The solution in the well was removed and 200 \il of D M S O was 
added. The plate was gently shaken for 1 hour at room temperature. Finally, the 
absorbance was read at 570 nm by using microplate spectrophotometer. The result 
was expressed as percentage of the control absorbance. 
5.2.7 Transport study 
The culture medium in both sides of the well was removed. The Caco-2 cell 
monolayer was washed twice with PBS+ and preincubated at 37°C for 15 minutes 
before the transport experiment was carried out. After preincubation, PBS+ in the 
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well was removed. 1.5 ml of PBS+ containing warfarin (50 jiM) and danshen extract 
(0.004, 0.02, 0.1 and 0.5 mg/ml) was added in the apical (AP) side. 2.6 ml of blank 
PBS+ was loaded in the basolateral (BL) side (Fig 5,1). 0.5 ml of samples was 
obtained from B L side at every 10 minutes. Same amount of blank PBS+ was added 
for replacement and keep the constant volume in B L side. The plate was kept in the 
incubator at 37°C between the time intervals. The whole transport experiment lasted 
for 50 minutes. After finishing the experiment, 0.5 ml of sample was also obtained 
from A L side. Besides, the T E E R was monitored again to ensure the integrity of 
Caco-2 cells monolayer. 50 \il of sample was mixed with 5 i^l of ethoxycoumarin 
(1.31 pmole，50 ^ g/ml) and 50 ]i\ of sample was injected to the H P L C for analysis. 
\\ / / 50 i^M warfarin & 
VA- / danshen extract in 1.5 
Caco-2 cells seeded \ \ i I / T ml PBS+ (AP side) 
on the microporous \ y • / 2.6 ml PBS+ 
membrane \ 丨^ (BL side) 
Fig 5.1 Caco-2 cells set up for drug absorption study 
5.2.8 Data Analysis 
The apparent permeability coefficient (Papp) was calculated by the following equation. 
Papp = (dC/dt X V) /(A X C) 
Where dC/dt is the change of drug concentration in the B L side (|^M/min), C is the 
initial concentration loaded on the AL side ()iM). V is the total volume of solution in 
• , 2 
BL side (ml) and A is the membranes surface area available for diffusion (cm ). 
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Data was expressed as the means 士 S E M of five determinations. Difference in Papp 
between treated and control groups was compared by Student's t-test that significant 




5.3.1 Stability of warfarin and danshen extract 
The stability of warfarin in PBS+ at pH 7.4 was assessed that warfarin was either 
incubated alone or with 1 mg/ml danshen extract at 37°C for 90 minutes. It was 
found that the amount of warfarin remained steady throughout the process which 
indicated that warfarin was stable at pH 7.4 (Fig 5.2). Therefore, pH 7.4 for PBS+ 
was used in the whole study. 
5.3.2 Toxicity test of danshen extract on Caco-2 cells 
There was no significant difference in the % of absorbance at all danshen extract 
concentration (0.125 to 2 mg/ml), indicating that danshen extract had no effect on the 
cell viability and thus no cytotoxicity effect on the Caco-2 cells (Fig 5.3). 
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1 • — ^ Warfarin and danshen extract 
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Fig.5.3 Effects of danshen extract on caco-2 cells in M T T assay. Data was 
normalised with the absorbance obtained in control group (100% of absorbance) and 
was expressed as mean 士 SEM, (n=6). 
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5.3.3 Integrity of Caco-2 cells monolayer 
The integrity of Caco-2 cells monolayer was measured by the TEER. The T E R R 
/-J 
values were found to be higher than 1319 ohm-cm before and after the experiment, 
which indicated that the integrity of Caco-2 cells monolayer maintained throughout 
the transport experiment and no destruction on the monolayer occurred. 
5.3.4 Transport study 
In the absorption transport study, danshen extract (0.004 to 0.1 mg/ml) had no 
significant effect on the absorption of warfarin. However, danshen extract (0.5 
mg/ml) increased the Papp value significantly, suggesting that danshen extract may 
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Fig.5.4 The apparent permeability coefficient (Papp) of warfarin with different 
concentration of danshen extract in the absorption study. Results were mean 士 S E M 




From the result of our pharmacokinetic study in Chapter 4, it appeared that the 
absorption or distribution phase related to the lower Cmax and delayed Tmax of 
warfarin in the danshen treated rats. In this Caco-2 absorption study, the permeability 
of warfarin obtained was similar to other published study, which is 15.34 士 1.1 x 10"^  
cm/s (Artursson & Karlsson, 1991). It was found that danshen extract (0.004 to 0.1 
mg/ml) had no effect on the permeability of warfarin but danshen extract (0.5 mg/ml) 
increased the permeability significantly. Besides, danshen extract was not affected 
the pH of the PBS+ buffer. Danshen may affect the permeability of warfarin by 
interfering its passive transcellular diffusion, which is the main transport mechanism 
for warfarin. However, other mechanisms may also be involved or affected by 
danshen. Danshen may affect the epithelial metabolism. It was found that the Caco-2 
cells exhibit CYP3A4 activity, which is one of major drug metabolizing enzyme for 
warfarin, therefore, danshen may have possibility to inhibit the intestinal CYP3A4 
and thus increased the permeability of warfarin. Nevertheless, the formation of 
metabolites cannot be measured as the detection limit of H P L C and thus this 
hypothesis cannot be proved. In addition, danshen may affect the paracellualar 
pathway between the cells and the transporters on the epithelial surface. 
Caco-2 cells model is widely used for in vitro drug absorption study as it shows 
several advantages. Firstly, the experimental setup is simple that the Caco-2 cells are 
just needed on the plate for its automatic differentiation before transport study. 
Besides, Caco-2 cells are derived from human origin and possess the characteristics 
of human intestinal cells. For the transport study, the drug can be added on either 
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side of a well and the samples for study the bidirectional transport in order to assess 
the extent of efflux. Nevertheless, Caco-2 cells also have its limitations that a long 
period (at least 21 days) is needed for the cells to fully differentiate and express the 
intestinal characteristics. In addition, Caco-2 cells do not produce mucus in the small 
intestine that may cause differences in the expression levels of drug uptake and 
efflux transporters. Furthermore, expressions of important drug metabolizing 
enzymes, such as cytochrome P450 was found much lower in the Caco-2 cells 
compared to the human intestine. Nevertheless, the intestinal CYP3A4 metabolism in 
human has been discovered that plays significantly role on the first-pass metabolism 
of many drugs (Watkins et al., 1987). In addition, the transporters in the caco-2 cells 
also showed higher or lower expression level than those in the intestine and thus the 
permeability may not extrapolate to the in vivo situation (Putnam et al., 2002). 
In conclusion, danshen extract (0.004 to 0.1 mg/ml) had no effect on the absorption 
of warfarin. This result may extrapolate to the in vivo situation that danshen extract 
may not affect the absorption phase of warfarin from 0 to 12 hours as observed in our 
in vivo rat studies in Chapter 4. More experiments can be carried out to see whether 
danshen affect other absorption mechanisms, such as, secretion, transporters and 
intestinal metabolism. Furthermore, other absorption cell culture models such as HT-







The use of T C M and natural products is becoming more popular in both Chinese 
communities and in western societies as an alternative medicine for the treatment of 
chronic diseases or as health supplement. To date, many T C M have been showed to 
have beneficial pharmacological effects in a number of illnesses as described in 
Chapter 1. However, the safe use of T C M and natural products remains a major 
concern with their increasing popularity. Apart from the quality control and toxicity 
of Chinese medicine, the issue on the potential TCM-drug interaction and their 
clinical significance remain uncertain (Williamson, 2003). Danshen is a widely used 
T C M for treatment of cardiovascular and cerebrovascular diseases in China. It has 
showed diverse pharmacological actions towards homeostasis and the circulatory 
system, such as, antiplatelet aggregation, coronary artery vasodilation, hypotensive 
effect, positive inotropic effect and negative chronotropic (Lei et al., 1986b; Li et al., 
1990; Tang et al, 2002). Previous studies have established that danshen extact 
exhibited both pharmacokinetic and pharmacodynamic interactions of warfarin in 
rats. Danshen extract increased the bioavailability and decreased the clearance of 
warfarin, and also prolonged the prothrombin time (Chan et al,, 1995). The results 
indicated that danshen extract altered the duration of action of warfarin and would 
lead to a potentially dangerous drug interaction. Clinical reports on the danshen-




The present studies investigated the underlying mechanism(s) of the pharmacokinetic 
interactions between danshen and warfarin. Our study focused on the effect of 
danshen on the metabolism of warfarin in vitro in rat and human liver to determine if 
danshen extract or its active ingredients affect the C Y P P450-mediated metabolism. 
The effects of danshen extract on the pharmacokinetics of warfarin in the rat m vivo 
were studied by using different dosing schedule. The steady state study aimed to 
mimic the situation where danshen was taken during steady-state warfarin. The 
single dose study aimed to mimic the situation when danshen was taken with 
warfarin at the early stages of warfarin therapy. 
In the rat liver microsomes study, the effects of danshen extract, aqueous extract, 
ethanolic extract, tanshinone I, IIA and cryptotanshinone on warfarin metabolism 
were compared. The danshen extract inhibited the formation of 4,- 6- and 7-
hydroxywarfarin, suggesting that it inhibited mainly on the CYPlAl, CYP2C6 and 
CYP2C11 mediated warfarin metabolism in vitro in rats (Fig 6.1). While the aqueous 
extract of danshen did not show significantly on warfarin metabolism, indicating that 
the water-soluble components of danshen may only inhibit at very high dose. The 
ethanolic extract was more potent than the danshen extract that inhibited the 
formation of all warfarin metabolites in ]ig/ml level, instead of mg/ml. For the 
isolated lipid-soluble components, tanshinone I significantly reduced the formation 
of 4，- and 6-hydroxywarfarin but no significant effect on the formation of 7-
hydroxywarfarin. This suggests that tanshinone I may only inhibit CYPlAl and 
CYP2C11 in rats which is mainly responsible for 4，- and 6- hydroxylation. On the 
other hand, tanshinone IIA inhibited the formation of 6- and 7-hydroxywafarin but 
had no effect on the formation of 4'-hydroxywarfarin. It may affect the activity of 
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CYP2C6 isoform for 7-hydroxylation and CYPlAl and CYP2C11 for 6-
hydroxylation. Cryptotanshinone was the most potent inhibitor on warfarin 
metabolism that the formation of 4’-, 6- and 7-hydroxywarfarin decreased 
significantly. The kinetics of the inhibition was determined. Cryptotanshinone was a 
pure competitive substrate for C Y P catalytic sites for warfarin metabolism. However, 
the type of inhibition for tanshinone I and IIA was less clear and may not be a simple 
competitive inhibition as discussed in Chapter 2. From the result, it suggests that 
different danshen components have different effects on the rat C Y P isoforms. It may 
inhibit the activity of CYCPlAl, CYP2B6 and CYP2C11 isoforms, mainly for the 
formation of 4，-, 6- and 7-hydroxwarfarin in the rats. 
In the pooled human liver microsomes study (Chapter 3), danshen extract and its 
components tested significantly inhibited the formation of 7-hydroxywarfarin with 
different extents. The result suggests that CYP2C9 mediated warfarin metabolism 
may be inhibited (Fig 6.2). However, the study did not give information about the 
CYP1A2 and CYP3A4 mediated pathways because other warfarin metabolites 
produced might be in minimal amount and below our H P L C detection limit. In 
addition to pooled human liver microsomes, human CYP2C9 isoform was also used 
in the present study. All danshen extract and its components again inhibited the 
formation of 7-hydroxywafarin, suggesting they are potential CYP2C9 inhibitors. 
Although the results from human liver microsomes studies were agreeable with the 
rat liver microsomes studies, the aqueous extract of danshen only showed inhibitory 
effects on the pooled human liver microsomes and human CYP2C9 isoform. This 
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Fig 6.1 The CYP-mediated metabolic pathways in the rat 
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Fig 6.2 The CYP-mediated metabolic pathways in man 
Our in vitro human and rat results were quite comparable to the study by Ueng in 
that tanshinone I, tanshinone IIA and cryptotanshinone believed to be involving in 
the C Y P inhibition, but with different potencies and specificities (Ueng et aL, 2003). 
Ueng showed that tanshinone I, tanshinone IIA and cryptotanshinone inhibited the 
rat C Y P I A isoform selectively without affecting other C Y P isoforms, CYP2C, 
CYP2E1 and CYP3A. Beside, tanshinone IIA was found to inhibit the human 
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C Y P 1 A 2 more selective than CYPlAl. However, tanshinone I and cryptotanshinone 
showed similar degree of inhibition on these two human C Y P isoforms. 
The in vivo studies in the rats enabled us to determine if the in vitro inhibition can be 
observed in vivo (Chapter 4). In the single dose study, both acute and subchronic 
pretreatment of danshen extract (300 and 400 mg/kg/twice daily) decreased the Cmax 
of warfarin significantly in the rats. On the other hand, pretreatment of danshen (400 
mg/kg/twice daily) prolonged Tmax significantly in both acute study and subchronic 
study. The alternation of Cmax and Tmax could not be explained in the present study 
that danshen extract may affect the pharmacokinetics of warfarin by several 
pathways. Nevertheless, our result showed difference from Chan's study, which 
danshen extract increased the A U C , Cmax, Un but decreased C L and Vd of warfarin 
(Chan et al” 1995). The differences may be caused by various preparation 
procedures of danshen extracts and danshen dosage (5 g/kg/twice daily) were used in 
Chan's study. 
Metabolic interaction is one of the possible interactions between danshen and 
warfarin. The amount of warfarin metabolites were significantly decreased by 
danshen (400 mg/kg/twice daily) in both acute and sub-chronic pretreatment studies. 
The result indicated that danshen extract may inhibit the P450-mediated warfarin 
metabolism in the rats so that less metabolites were formed. Furthermore, the plasma 
warfarin concentration elevated significantly by 23% in the danshen treatment period 
during the oral administration of steady state of warfarin. The increased warfarin 
concentration could be explained by the decreased of warfarin clearance as danshen 
extract might inhibit the liver C Y P activity. For those evidences, danshen was 
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believed to inhibit the C Y P isoforms for warfarin metabolism in both in vivo and in 
vz>o situation. Nevertheless, some papers found that C Y P activities increased 
significantly after chronic treatment of danshen extract and tanshinones in rats 
(Jinping et al., 2003; Yang et al., 2003). 
Apart from the proposed metabolic interaction, danshen may have possibility to 
affect the absorption of warfarin. The effect of danshen extract on the absorption of 
warfarin was studied by Caco-2 cells model (Chapter 5). There was no significant 
different on the permeability of warfarin at danshen extract doses (0.004 to 0.1 
mg/ml) and only danshen extract (0.5 mg/ml) increased the permeability significantly. 
This absorption study showed that low dose of danshen extract may not affect the 
absorption of warfarin. However, more transport experiments should be carried out 
to see if danshen extract or its components have any effects on transporters and 
enzymes on the intestine epithelium. 
In conclusion, danshen extract and its components were found to inhibit CYP2C9 
mediated warfarin metabolism in human liver microsomes. As broad substrate 
specificity is a characteristic of CYP, this implies that danshen extract may interact 
with of other coadministered drugs that are metabolized by CYP2C9 isoforms, like 
antipyrine and tolbutamide. From the single dose study, it implies that the initial 
plasma warfarin concentration may be lowered than expected in patients who have 
taken danshen previously before warfarin therapy. On the other hand, over-
anticoagulation maybe observed in patents who have taken danshen and warfarin 
together, which was indicated by steady state study. It is important for patients to 
report whether they have consumed danshen or other T C M supplement before and 
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during the warfarin therapy in order to prevent the adverse TCM-warfarin 
interactions. 
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